[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 67 of about 67
1. Batyraliev TA, Fetser DV, Preobrazhenskiĭ DV, Pershukov IV, Sidorenko BA: [Percutaneous coronary interventions on unprotected left main coronary artery: contemporary outlook of the problem]. Kardiologiia; 2009;49(5):81-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Percutaneous coronary interventions on unprotected left main coronary artery: contemporary outlook of the problem].
  • Coronary bypass surgery in patients with lesions in unprotected left main coronary artery (LMCA) remains gold standard of treatment.
  • Is PCI of LMCA justified, what is complication rate of PCI of LMCA?
  • In order to answer these questions we analyzed modern studies in which PCI with the use of standard metal and drug eluting stents were carried out in patients with lesions in unprotected LMCA.
  • [MeSH-major] Angioplasty, Balloon, Coronary / methods. Coronary Disease / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463146.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 39
  •  go-up   go-down


2. Qarawani D, Menachem N, Ganem D, Hasin Y: Unprotected left main stenting, short- and long-term outcomes. Acute Card Care; 2010 Dec;12(4):124-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unprotected left main stenting, short- and long-term outcomes.
  • BACKGROUND: Coronary bypass surgery is recommended for the treatment of left main coronary stenosis.
  • OBJECTIVES: To present the in-hospital and long-term clinical and angiographic outcome of a consecutive group of patients undergoing stenting for unprotected left main coronary artery (LMCA) disease, and to compare the clinical and angiographic outcomes of drug-eluting stent (DES) versus metal stent (BMS).
  • METHODS: 238 consecutive patients underwent unprotected LMCA stenting.
  • Drug-eluting stent implantation for unprotected LMCA stenosis appears safe with regard to acute and long-term complications and is more effective in preventing restenosis compared to BMS implantation.
  • [MeSH-major] Acute Coronary Syndrome / therapy. Coronary Artery Disease / therapy. Drug-Eluting Stents
  • [MeSH-minor] Aged. Angioplasty, Balloon, Coronary / adverse effects. Angioplasty, Balloon, Coronary / contraindications. Coronary Artery Bypass / adverse effects. Coronary Artery Bypass / contraindications. Coronary Vessels / pathology. Coronary Vessels / surgery. Follow-Up Studies. Hospital Mortality. Humans. Long-Term Care. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039084.001).
  • [ISSN] 1748-295X
  • [Journal-full-title] Acute cardiac care
  • [ISO-abbreviation] Acute Card Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Kim HS, Kim YH, Lee SW, Park DW, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ: Safety and effectiveness of sirolimus-eluting stent implantation for in-stent restenosis of the unprotected left main coronary artery. Int J Cardiol; 2008 Feb 20;124(1):118-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and effectiveness of sirolimus-eluting stent implantation for in-stent restenosis of the unprotected left main coronary artery.
  • The present study examined the alternative treatment of sirolimus-eluting stent (SES) implantation for in-stent restenosis (ISR) of the unprotected left main coronary artery (LMCA).
  • Twelve patients underwent SES deployment for bare-metal ISR in the LMCA.
  • ISR were 24+/-11 mm in length and located at the ostial (n=1) and distal (n=11) portion of LMCA.
  • Bifurcation lesions were treated with one of three techniques: the stent crossing the left circumflex artery (n=7), kissing stenting (n=2) or the Crush technique (n=2).
  • There were no cases of significant narrowing in the left circumflex artery after the procedure.
  • The present study suggests that SES implantation may be a feasible therapeutic option for treating ISR in unprotected LMCA.
  • [MeSH-major] Coronary Restenosis / therapy. Drug-Eluting Stents. Graft Occlusion, Vascular / therapy. Immunosuppressive Agents / administration & dosage. Sirolimus / administration & dosage

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383034.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


Advertisement
4. Van Mieghem CA, Cademartiri F, Mollet NR, Malagutti P, Valgimigli M, Meijboom WB, Pugliese F, McFadden EP, Ligthart J, Runza G, Bruining N, Smits PC, Regar E, van der Giessen WJ, Sianos G, van Domburg R, de Jaegere P, Krestin GP, Serruys PW, de Feyter PJ: Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. Circulation; 2006 Aug 15;114(7):645-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound.
  • BACKGROUND: Surveillance conventional coronary angiography (CCA) is recommended 2 to 6 months after stent-supported left main coronary artery (LMCA) percutaneous coronary intervention due to the unpredictable occurrence of in-stent restenosis (ISR), with its attendant risks.
  • We evaluated the diagnostic performance of high-resolution MSCT to detect ISR after stenting of the LMCA.
  • METHODS AND RESULTS: Seventy-four patients were prospectively identified from a consecutive patient population scheduled for follow-up CCA after LMCA stenting and underwent MSCT before CCA.
  • The sensitivity, specificity, and positive and negative predictive values were 100%, 91%, 67%, and 100%, respectively.
  • When analysis was restricted to patients with stenting of the LMCA with or without extension into a single major side branch, accuracy was 98%.
  • When both branches of the LMCA bifurcation were stented, accuracy was 83%.
  • CONCLUSIONS: Current MSCT technology, in combination with optimal heart rate control, allows reliable noninvasive evaluation of selected patients after LMCA stenting.
  • MSCT is safe to exclude left main ISR and may therefore be an acceptable first-line alternative to CCA.
  • [MeSH-minor] Adrenergic beta-Antagonists / pharmacology. Aged. Coronary Artery Disease / physiopathology. Coronary Artery Disease / therapy. Coronary Vessels / physiopathology. Coronary Vessels / ultrasonography. Female. Heart Rate / drug effects. Heart Rate / physiology. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Risk Factors. Sensitivity and Specificity. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Circulation. 2006 Aug 15;114(7):616-9 [16908783.001]
  • (PMID = 16894038.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists
  •  go-up   go-down


5. Nelson ME, Steensma DP: JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma; 2006 Feb;47(2):177-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
  • Until very recently, the only TK mutations widely observed in myeloid neoplasia were the BCR/ABL1 fusions characteristic of chronic myeloid leukemia and some acute leukemias, and FLT3 activating mutations in a minority of acute myeloid leukemias.
  • Several rare TK mutations are found in various atypical myeloproliferative disorders, but big pieces of the pathobiological puzzle were glaringly missing.
  • In the first half of 2005, one gap was filled in: 7 studies identified the same acquired amino acid substitution (V617F) in the Janus kinase 2 (JAK2) TK in large numbers of patients with diverse clonal myeloid disorders.
  • Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metaplasia (44% of n = 127) bear the identical mutation, as do a few individuals with myelodysplastic syndromes or an atypical myeloid disorder (7% of n = 556).
  • This long-sought common mutation in BCR/ABL1-negative MPD raises many provocative biological and clinical questions, and demands re-evaluation of prevailing diagnostic algorithms for erythrocytosis and thrombocytosis.
  • JAK2 V617F may provide novel molecular targets for drug therapy, and suggests other places to seek cooperating mutations or mutations associated with similar phenotypes.
  • The story of this exciting finding will unfold rapidly in the years ahead, and ongoing developments will be important for all hematologists to understand.
  • [MeSH-major] Myeloproliferative Disorders / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Animals. Humans. Janus Kinase 2. Mutation. Signal Transduction / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Lymphoma. 2006 May;47(5):957
  • (PMID = 16321848.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA 90628
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 143
  •  go-up   go-down


6. Khattab AA, Hamm CW, Senges J, Toelg R, Geist V, Bonzel T, Kelm M, Levenson B, Neumann FJ, Nienaber CA, Pfannebecker T, Sabin G, Schneider S, Tebbe U, Richardt G, German Cypher Registry: Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry. Heart; 2007 Oct;93(10):1251-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry.
  • BACKGROUND: Percutaneous coronary intervention (PCI) of left main coronary artery (LMCA) disease in the bare stent era was limited by high restenosis rates which eventually resulted in sudden death in unprotected cases.
  • Clinical and angiographic restenosis has been substantially reduced by drug-eluting stents, reviving therefore this indication for PCI despite the absence of direct comparative studies with coronary artery bypass graft surgery.
  • OBJECTIVE: To assess the acute, mid- and long-term outcomes of patients treated with sirolimus-eluting stents for unprotected LMCA stenoses and to compare them with those treated for protected LMCA disease in the same time period from the German Cypher Registry.
  • Eighty-two patients treated for unprotected LMCA disease were compared with 118 patients treated for protected LMCA stenoses.
  • RESULTS: One-third of the patients in both groups were treated for the distal left main bifurcation.
  • The cumulative combined incidence of all-cause death, non-fatal MI and target vessel revascularisation at 6 months was 14.1% in the unprotected LMCA group and 13.1% in the protected group (hazard ratio = 0.81 (95% CI 0.37 to 1.74), p = 0.8).
  • CONCLUSION: Sirolimus-eluting stent treatment of unprotected and protected LMCA stenoses is technically feasible in widespread routine clinical use.
  • Acceptable long-term clinical results can be achieved, with no particular safety concerns about treatment of unprotected LMCA disease.
  • [MeSH-minor] Aged. Disease-Free Survival. Drug Implants. Female. Follow-Up Studies. Humans. Male. Prospective Studies. Registries. Treatment Outcome

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2001 Mar 1;37(3):832-8 [11693759.001]
  • [Cites] Herz. 2004 Mar;29(2):181-6 [15057439.001]
  • [Cites] J Am Coll Cardiol. 2006 Feb 21;47(4):871-7 [16487858.001]
  • [Cites] J Am Coll Cardiol. 2006 Feb 21;47(4):864-70 [16487857.001]
  • [Cites] Z Kardiol. 2004 Apr;93(4):287-94 [15085373.001]
  • [Cites] Circulation. 1967 Jul;36(1):54-62 [6027214.001]
  • [Cites] Circulation. 1983 Nov;68(5):939-50 [6137292.001]
  • [Cites] Circulation. 1995 May 1;91(9):2325-34 [7729018.001]
  • [Cites] J Am Coll Cardiol. 2005 Feb 1;45(3):351-6 [15680711.001]
  • [Cites] Circulation. 2005 Feb 15;111(6):791-5 [15699254.001]
  • [Cites] Circulation. 2005 Mar 22;111(11):1383-9 [15781749.001]
  • [Cites] J Am Coll Cardiol. 2006 Jan 3;47(1):216-35 [16386696.001]
  • [ErratumIn] Heart. 2009 Dec;95(24):2029
  • [ErratumIn] Heart. 2010 Mar;96(6):471
  • [ErratumIn] Heart. 2010 Dec;96(24):2044
  • (PMID = 17890701.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Tubulin Modulators; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2000930
  •  go-up   go-down


7. Tespili M, Saino A, Personeni D, Silvestro A, Scopelliti P, Banfi C: Life-threatening left main stenosis induced by compression from a dilated pulmonary artery. J Cardiovasc Med (Hagerstown); 2009 Feb;10(2):183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-threatening left main stenosis induced by compression from a dilated pulmonary artery.
  • On a rare occasion, pulmonary artery dilatation can be complicated by an extrinsic compression of the left main coronary artery (LMCA) whose effects are immediately evident, whereas a delayed presentation is unusual.
  • We report the uncommon case of a delayed acute coronary syndrome caused by the extrinsic compression of the LMCA due to pulmonary artery enlargement and the potential problems related to its management.
  • An 82-year-old woman with a history of severe chronic obstructive pulmonary disease, a previous episode of deep venous thrombosis and a computed tomography-documented pulmonary artery dilatation was referred to the emergency room for worsening dyspnoea and chest pain.
  • Urgent coronary angiography showed severe LMCA stenosis caused by extrinsic compression from the pulmonary artery with no other lesions in the coronary arteries; coronary angioplasty was successfully performed with a direct drug-eluting stent implantation that led to a significant improvement of the haemodynamic conditions in the following days.
  • Planned control angiography performed 10 days later showed the recurrence of the LMCA stenosis together with a forward displacement of the previously implanted drug-eluting stent, which was managed with a further direct implantation of a bare metal stent.
  • [MeSH-major] Acute Coronary Syndrome / etiology. Coronary Stenosis / etiology. Pulmonary Artery / physiopathology. Shock, Cardiogenic / etiology. Vasodilation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377383.001).
  • [ISSN] 1558-2027
  • [Journal-full-title] Journal of cardiovascular medicine (Hagerstown, Md.)
  • [ISO-abbreviation] J Cardiovasc Med (Hagerstown)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Wu XM, Liu CP, Lin WC, Kao HL: Long-term outcome of percutaneous coronary intervention for unprotected left main coronary artery disease. Int J Cardiol; 2010 Feb 4;138(3):272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of percutaneous coronary intervention for unprotected left main coronary artery disease.
  • OBJECTIVES: The aim of this study is to evaluate the in-hospital, 30 day and long-term outcomes after percutaneous coronary intervention for unprotected left main coronary artery disease.
  • BACKGROUNDS: Left main coronary artery (LMCA) diseases stenosis is a strong indication for coronary artery bypass grafting (CABG).
  • With improved device technology, percutaneous coronary intervention (PCI) with drug-eluting stent (DES) stents had been recently advocated as an alternative procedure for the unprotected LMCA disease.
  • METHODS: Between January 2003 and February 2007, all unprotected LMCA PCI procedures were retrospectively collected.
  • RESULTS: Fifty five consecutive patients with >50% diameter stenosis of LMCA undergoing PCI were analyzed.
  • Indications for a percutaneous strategy were prohibitive surgical risks, or patient/physician preference.
  • CONCLUSIONS: Our results showed that PCI with stenting was an acceptable treatment option for patients with LMCA stenosis.
  • Involvement of the LMCA bifurcation remains a predictor for unfavorable outcome.
  • [MeSH-major] Angioplasty, Balloon, Coronary / mortality. Coronary Artery Disease / mortality. Coronary Artery Disease / therapy. Drug-Eluting Stents / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Elsevier Ireland Ltd. All rights reserved.
  • [CommentIn] Int J Cardiol. 2010 Sep 24;144(1):90-1 [19157586.001]
  • (PMID = 18804295.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer; 2003 Jun 1;97(11):2760-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
  • BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R).
  • c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD).
  • Forty-eight patients with AML (n = 10), MDS (n = 8), myelofibrosis (n = 18), atypical chronic myeloid leukemia (CML; n = 7), chronic myelomonocytic leukemia (CMML; n = 3), or polycythemia vera (n = 2) were treated with imatinib 400 mg daily.
  • One patient with atypical CML had erythroid hematologic improvement.
  • The side effects were similar to those observed in patients with CML.
  • CONCLUSIONS: Within these small subgroups of disease types, single-agent imatinib did not achieve a significant clinical response among patients with AML, MDS, atypical CML, or CMML without PDGF-R fusion genes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Myeloproliferative Disorders / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelomonocytic, Chronic / drug therapy. Middle Aged. Polycythemia Vera / drug therapy. Primary Myelofibrosis / drug therapy. Recurrence


10. Ng MK, Yeung AC: Left main coronary artery disease: is CABG still the gold standard? Rev Cardiovasc Med; 2005;6(4):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left main coronary artery disease: is CABG still the gold standard?
  • Severe stenosis of the left main coronary artery (LMCA) is a coronary artery-disease manifestation of critical prognostic importance.
  • As a consequence of the survival advantage conferred by coronary artery bypass grafting (CABG) over medical therapy, lesions in the LMCA have been considered a standard indication for CABG for nearly 3 decades.
  • Initial attempts to treat LMCA disease percutaneously by balloon angioplasty resulted in poor clinical outcomes, leading many to regard significant LMCA disease as a contraindication for percutaneous coronary intervention (PCI).
  • However, the development and refinement of coronary stenting over the last 15 years, followed by the recent introduction of drug-eluting stents, has fueled renewed interest in percutaneous treatment of LMCA disease.
  • Outcomes of recent studies using sirolimus- and/or paclitaxel-eluting stents for treatment of LMCA disease have yielded rates of in-hospital and 1-year mortality that compare favorably with those of surgery.
  • This article will review the natural history of LMCA disease, the outcomes of CABG for LMCA disease, and the history and recent developments regarding PCI for LMCA disease.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Artery Disease / therapy. Coronary Stenosis / therapy. Stents


11. Murasato Y, Horiuchi M, Otsuji Y: Three-dimensional modeling of double-stent techniques at the left main coronary artery bifurcation using micro-focus X-ray computed tomography. Catheter Cardiovasc Interv; 2007 Aug 1;70(2):211-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional modeling of double-stent techniques at the left main coronary artery bifurcation using micro-focus X-ray computed tomography.
  • BACKGROUND: Various double-stent techniques using drug-eluting stents have been proposed to treat the left main coronary artery (LMCA) bifurcation.
  • However, use of these techniques is frequently associated with focal restenosis at the ostium of the left circumflex coronary artery (LCX).
  • OBJECTIVES: To examine the results of double-stent techniques, using a silicon model of the LMCA bifurcation and three-dimensional (3D) reconstruction images created with micro-focus X-ray computed tomography (MFCT).
  • METHODS: Crush, kissing, and modified T stentings were performed with bare metal stents in a LMCA bifurcation model.
  • The stents were then inspected using MFCT at a minimal resolution of 0.06 mm.
  • RESULTS: Gaps in stent apposition to the vessel were observed at the site of stent overlap in the distal LMCA with all stenting techniques.
  • In crush stenting, when the left anterior descending artery stent overlapped the LCX stent, the latter was crushed on the myocardial side of the vessel, and a gap was observed on the nonmyocardial side, at the LCX ostium.
  • CONCLUSIONS: Close apposition of the stent to the vessel at the ostium of the LCX is difficult to achieve at the LMCA bifurcation, regardless of which double-stent technique is employed, due to the site's wide bifurcation angle and complex 3D structure.
  • [MeSH-major] Blood Vessel Prosthesis. Blood Vessel Prosthesis Implantation / instrumentation. Coronary Angiography / methods. Coronary Artery Disease / radiography. Imaging, Three-Dimensional. Radiographic Image Interpretation, Computer-Assisted. Stents. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17421017.001).
  • [ISSN] 1522-1946
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


12. Ma YH, Cheng WZ, Gong F, Ma AL, Yu QW, Zhang JY, Hu CY, Chen XH, Zhang DQ: Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses. World J Gastroenterol; 2008 Sep 14;14(34):5274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the potential role of active Chinese mistletoe lectin-55 (ACML-55) in tumor immune surveillance.
  • The experimental treatment was orally administered with ACML-55 or PBS, followed by the inoculation of colon cancer cell line CT26.
  • RESULTS: Our results showed, compared to PBS treated mice, ACML-55 treatment significantly delayed colon cancer development in colon cancer-bearing Balb/c mice in vivo.
  • Treatment with ACML-55 enhanced both Ag specific activation and proliferation of CD4+ and CD8+ T cells, and increased the number of tumor Ag specific CD8+ T cells.
  • Interestingly, ACML-55 treatment also showed increased cell number of NK, and gammadeltaT cells, indicating the role of ACML-55 in activation of innate lymphocytes.
  • CONCLUSION: Our results demonstrate that ACML-55 therapy can enhance function in immune surveillance in colon cancer-bearing mice through regulating both innate and adaptive immune responses.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colonic Neoplasms / immunology. Colonic Neoplasms / prevention & control. Drugs, Chinese Herbal / pharmacology. Mistletoe. Plant Lectins / pharmacology
  • [MeSH-minor] Animals. CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Cell Line, Tumor. Disease Models, Animal. Female. Immunity, Innate / drug effects. Interferon-gamma / biosynthesis. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Lymphocyte Activation / drug effects. Male. Mice. Mice, Inbred BALB C. Monitoring, Immunologic. Phytotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2002 Oct;60(4):640-4 [12385925.001]
  • [Cites] Nat Rev Immunol. 2002 May;2(5):336-45 [12033739.001]
  • [Cites] Urology. 2004 Feb;63(2):259-63 [14972467.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3151-6 [15457562.001]
  • [Cites] Oncology. 1986;43 Suppl 1:51-65 [2433654.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3646-51 [1692765.001]
  • [Cites] Cancer Lett. 1990 May 30;51(2):103-8 [2344587.001]
  • [Cites] Cancer Immunol Immunother. 1990;32(4):221-7 [2124513.001]
  • [Cites] Cancer Immunol Immunother. 1993;36(4):237-44 [8439987.001]
  • [Cites] Cancer Lett. 1996 Jan 19;99(1):59-72 [8564930.001]
  • [Cites] Immunol Lett. 1996 Sep;52(2-3):69-72 [8905398.001]
  • [Cites] Cancer Lett. 1996 Dec 3;109(1-2):33-8 [9020900.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8 Suppl 1:S33-7 [9179365.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8 Suppl 1:S39-42 [9179366.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8 Suppl 1:S53-5 [9179369.001]
  • [Cites] Arzneimittelforschung. 1997 Oct;47(10):1145-51 [9368710.001]
  • [Cites] Cell Mol Life Sci. 1999 Apr;55(4):679-82 [10357236.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1521-9 [15547686.001]
  • [Cites] Toxicology. 2005 Feb 1;207(1):105-16 [15590126.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):5783-9 [16237070.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2007 Jun;39(6):445-52 [17558450.001]
  • [Cites] World J Gastroenterol. 2007 May 28;13(20):2811-8 [17569116.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3056-64 [10706694.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1118-22 [11590434.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1566-71 [11823483.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109 [11900986.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):433-42 [12900519.001]
  • (PMID = 18785279.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Plant Lectins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2744057
  •  go-up   go-down


13. Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A, Kim YH, Valgimigli M, Sillano D, Magni V, Biondi-Zoccai G, Montorfano M, Airoldi F, Rogacka R, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Sangiorgi GM, Tobis J, Serruys PW, Colombo A: Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J; 2008 Sep;29(17):2108-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry.
  • AIMS: To evaluate the occurrence of late and very late stent thrombosis (ST) following elective drug-eluting stent (DES) implantation in unprotected left main coronary artery (LMCA) stenosis in a large multicentre registry.
  • METHODS AND RESULTS: All 731 consecutive patients who had sirolimus- or paclitaxel-eluting stent electively implanted in de novo lesions on unprotected LMCA in five centres were included.
  • Four (0.5%) patients had a definite ST: three early (two acute and one subacute) and one late ST, no cases of very late definite ST were recorded.
  • Therefore, 7/731 (0.95%) patients had a definite or a probable ST and all were on dual antiplatelet therapy at the time of the event.
  • CONCLUSION: Elective treatment of LMCA stenosis with DES appears safe with a 0.9% incidence of definite and probable ST at 29.5 ± 13.7 months.
  • [MeSH-major] Coronary Restenosis / prevention & control. Drug-Eluting Stents. Graft Occlusion, Vascular / etiology. Paclitaxel / administration & dosage. Sirolimus / administration & dosage. Tubulin Modulators / administration & dosage

  • Genetic Alliance. consumer health - Thrombosis.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Heart J. 2008 Sep;29(17):2064-6 [18664463.001]
  • (PMID = 18565967.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


14. Murasato Y: Impact of three-dimensional characteristics of the left main coronary artery bifurcation on outcome of crush stenting. Catheter Cardiovasc Interv; 2007 Feb 1;69(2):248-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of three-dimensional characteristics of the left main coronary artery bifurcation on outcome of crush stenting.
  • BACKGROUND: Crush stenting with drug-eluting stents is used to treat left main coronary artery (LMCA) bifurcations.
  • However, the rate of restenosis at the left circumflex (LCX) artery ostium is high.
  • The impact of the three-dimensional (3D) structure of LMCA bifurcation on the outcome of crush stenting with respect to restenosis has not been described.
  • OBJECTIVES: This study examined the stent expansion, deformity, overlapping, and apposition after crush stenting of LMCA bifurcations.
  • METHODS: Bare metal stents were crushed at LMCA bifurcations in a 3D model that reproduced actual angles, such that the stent deployed from the LMCA to the left anterior descending (LAD) artery crushed the stent deployed from the LMCA to the LCX, followed by kissing balloon inflation.
  • RESULTS: In the 3D model, one stent overlapped the other in the distal LMCA, in contrast to the nearly parallel position of the stents observed in a separate two-dimensional model.
  • A narrow LMCA-LCX angle was associated with less expansion of the LCX stent at the ostium than more distally, and with a higher likelihood of incomplete stent apposition.
  • CONCLUSIONS: Overlap of the LAD stent over, as opposed to under, the LCX stent was associated with close apposition of the stent to the vessel on the myocardial side, at the ostium of the LCX artery, where atherosclerotic plaques are likely to be present.
  • The spatial plaque burden and bifurcation angle should be closely examined before crush stenting, and segments should not be left unstented over large plaques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17211894.001).
  • [ISSN] 1522-1946
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Zhang Y, Qiu JY, Lai YY, Lu DP: Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases. Int J Hematol; 2004 Aug;80(2):159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases.
  • The term subacute myeloid leukemia is not present in most hematologic textbooks, but clinically the disease does exist.
  • None of the patients had been given cytotoxic drugs before the leukemia became apparent.
  • At a median follow-up period of 21.5 months (range, 3-129 months), the median overall survival time was 20 months for all of the patients with +8, including the patients with chromosome abnormalities in addition to +8.
  • In the group with +8 only, 11 (45.8%) of the 24 patients developed frank leukemia, and 9 of these 11 patients died.
  • The diseases of these patients manifested an insidious onset and a subacute but progressive clinical course, and they all had cytogenetic clonal changes with +8.
  • These facts suggest that this group of +8 patients all had evidence of a leukemic clone, and their conditions might conform to the diagnosis of subacute myeloid leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Trisomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Diagnosis, Differential. Female. Humans. Karyotyping. Male. Middle Aged. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1963 Apr 11;268:812-5 [13981961.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):839-48 [10996202.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):346-56 [10691865.001]
  • [Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1315-23 [8371581.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 15;124(2):159-64 [11172910.001]
  • [Cites] Am J Clin Pathol. 1950 Jun;20(6):562-79 [15432355.001]
  • [Cites] Blood Cells Mol Dis. 2000 Dec;26(6):572-81 [11112390.001]
  • [Cites] Am J Hematol. 1997 Dec;56(4):224-9 [9395183.001]
  • (PMID = 15481445.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Godino C, Parodi G, Furuichi S, Latib A, Barbagallo R, Goktekin O, Cera M, Mueller R, Tamburino C, Grube E, Di Mario C, Reimers B, Chieffo A, Antoniucci D, Colombo A, Sangiorgi GM: Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention; 2010 Apr;5(8):906-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry).
  • AIMS: Limited data are available on the long-term outcome following PCI with paclitaxel-eluting stent (PES) implantation in patients with unprotected left main coronary artery (LMCA).
  • The objective of this study was to evaluate "real world" long-term outcome following paclitaxel-eluting stent (PES) implantation for unprotected LMCA disease in patients enrolled in the TRUE registry.
  • METHODS AND RESULTS: From March 2003 to October 2004, 93 consecutive patients (81.7% male) underwent PCI for unprotected LMCA disease.
  • The target lesion involved the distal LMCA in 68 (73.1%) patients.
  • Double stenting techniques were performed in 46 (67.6%) distal LMCA, of these 50% were stented using the Crush technique.
  • In-segment restenosis occurred in 16 (20.3%) patients and was focal in 72.4% of cases and significantly higher in patients with distal LMCA (36.8% vs. 13.6%, p<0.04).
  • At a median follow-up of 1,450 days (IQR 1281-1595), the overall incidence of MACE was 35.5% and the TLR rate was 25.8% and significantly higher in patients with bifurcation stenting (32.3% vs. 8%, p<0.02).
  • CONCLUSIONS: Treatment of unprotected LMCA disease with PES, after four years follow-up, appears to be safe and effective with a low rate of cardiac mortality and overall risk of ST.
  • The need for target lesion revascularisation in 25.8% of patients highlights the need for more effective PCI especially in patients with distal LMCA disease.
  • [MeSH-major] Angioplasty, Balloon, Coronary / instrumentation. Cardiovascular Agents / administration & dosage. Coronary Artery Disease / therapy. Drug-Eluting Stents. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Coronary Angiography. Coronary Restenosis / etiology. Disease-Free Survival. Europe / epidemiology. Female. Follow-Up Studies. Hospital Mortality. Humans. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Myocardial Infarction / etiology. Prosthesis Design. Registries. Risk Assessment. Risk Factors. Severity of Illness Index. Thrombosis / etiology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] EuroIntervention. 2011 Feb;6(7):904-5 [21252030.001]
  • (PMID = 20542775.001).
  • [ISSN] 1969-6213
  • [Journal-full-title] EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • [ISO-abbreviation] EuroIntervention
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cardiovascular Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Hsu JT, Chu CM, Chang ST, Kao CL, Chung CM: Percutaneous coronary intervention versus coronary artery bypass graft surgery for the treatment of unprotected left main coronary artery stenosis: in-hospital and one year outcome after emergent and elective treatments. Int Heart J; 2008 May;49(3):355-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous coronary intervention versus coronary artery bypass graft surgery for the treatment of unprotected left main coronary artery stenosis: in-hospital and one year outcome after emergent and elective treatments.
  • This study attempts to compare the risks and benefits of provisional stenting with drug eluting stents and bypass surgery for left main coronary artery (LMCA) stenosis.
  • Recent improvements in interventional technologies have increased interest in percutaneous treatment of LMCA stenosis.
  • However, application of percutaneous techniques to LMCA has been sporadic and controversial.
  • In-hospital and one year outcomes of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) cases were compared.
  • From September, 2003 to June, 2005, a total of 59 consecutive patients with de novo unprotected LMCA stenosis were treated with either CABG or PCI.
  • Twenty patients received non-intravascular ultrasound-guided PCI with a stent in the LMCA.
  • At 30-day follow-up, the major adverse cardiac and cerebrovascular event (MACE) rates of mortality, myocardial infarction, cerebral vascular accident, and target vessel revascularization were 25.6% in the CABG group and 5% in the PCI group (P=0.054).
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Stenosis / therapy
  • [MeSH-minor] Aged. Drug-Eluting Stents. Female. Humans. Male. Middle Aged. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612192.001).
  • [ISSN] 1349-2365
  • [Journal-full-title] International heart journal
  • [ISO-abbreviation] Int Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Hasegawa T, Ako J, Koo BK, Miyazawa A, Sakurai R, Chang H, Dens J, Verheye S, Grube E, Honda Y, Fitzgerald PJ: Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial. Catheter Cardiovasc Interv; 2009 Jan 1;73(1):34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial.
  • OBJECTIVE: To assess the efficacy of the AXXESS stent on the treatment of left main coronary artery (LMCA) bifurcation lesions using IVUS.
  • BACKGROUND: The treatment of LMCA bifurcation lesions remains challenging even with the use of drug-eluting stents.
  • METHODS: Data were obtained from the AXXENT trial, a prospective, single-arm, multicenter study designed to evaluate the efficacy of the AXXESS stent on the treatment of LMCA bifurcation lesions.
  • Volumetric and cross-sectional analyses within the AXXESS stent, and cross-sectional analyses at the ostia of left anterior descending (LAD) and left circumflex coronary arteries (LCX) were performed.
  • CONCLUSIONS: The AXXESS stent in the LMCA showed enlargement through 6-months follow-up and significant neointimal suppression.
  • [MeSH-major] Alloys. Angioplasty, Balloon, Coronary / instrumentation. Cardiovascular Agents / administration & dosage. Coronary Stenosis / therapy. Drug-Eluting Stents. Sirolimus / analogs & derivatives. Stents. Ultrasonography, Interventional

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [CommentIn] Catheter Cardiovasc Interv. 2009 Jan 1;73(1):42-3 [19089935.001]
  • (PMID = 19089934.001).
  • [ISSN] 1522-726X
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alloys; 0 / Biolimus A9; 0 / Cardiovascular Agents; 52013-44-2 / nitinol; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


19. Wu C, Hannan EL, Walford G, Faxon DP: Utilization and outcomes of unprotected left main coronary artery stenting and coronary artery bypass graft surgery. Ann Thorac Surg; 2008 Oct;86(4):1153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization and outcomes of unprotected left main coronary artery stenting and coronary artery bypass graft surgery.
  • BACKGROUND: Limited contemporary information is available on outcomes for patients with unprotected left main coronary artery (LMCA) disease who are revascularized.
  • METHODS: We examined the relative frequency, severity of illness, and outcomes of stenting and coronary artery bypass graft (CABG) surgery for treating unprotected LMCA disease in New York between January 1, 2000 and December 31, 2004.
  • A total of 135 stent patients were matched to 135 CABG patients on baseline characteristics identified by a propensity model as predictors of type of procedure received.
  • In the drug-eluting stent era between October 1, 2003 and December 31, 2004, the same trends in mortality (hazard ratio = 0.73, p = 0.69) and repeat revascularization (hazard ratio = 0.10, p = 0.03) were observed among the 56 pairs of matched CABG and drug-eluting stent patients.
  • CONCLUSIONS: Most patients with LMCA disease who needed coronary revascularization received CABG surgery; stent patients were sicker.
  • However, more studies comparing these procedures are needed, especially in the drug-eluting stent era.
  • [MeSH-major] Angioplasty, Balloon, Coronary / methods. Cause of Death. Coronary Artery Bypass / methods. Coronary Stenosis / mortality. Coronary Stenosis / therapy. Stents

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 May;87(5):1651-2; author reply 1652-3 [19379945.001]
  • (PMID = 18805151.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Nomura T, Nakagawa Y, Urakabe Y, Naito D, Enomoto S, Nishikawa S, Keira N, Matsubara H, Tatsumi T: Subacutely progressed extensive aortic dissection complicated with catheter-induced dissection in left main coronary artery. J Cardiol; 2009 Aug;54(1):128-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subacutely progressed extensive aortic dissection complicated with catheter-induced dissection in left main coronary artery.
  • A 64-year-old man complaining of resting angina underwent emergent coronary angiogram and significant stenosis in the mid-left anterior descending artery was discovered.
  • Although deployment of the drug-eluting Cypher stent relieved the stenosis, the guiding catheter accidentally induced coronary dissection in the left main coronary artery (LMCA).
  • 20 days later, although asymptomatic, extensive aortic dissection was detected from the coronary sinus of Valsalva to the femoral artery.
  • 64-Row multidetector computed tomography demonstrated that the dissection originated from the LMCA and retrogradely expanded to the aorta.
  • This type of dissection is a rare complication related to coronary intervention and even in such a clinical setting, asymptomatic delayed progression of retrograde aortic dissection has not previously been reported to our knowledge.
  • [MeSH-major] Aneurysm, Dissecting / complications. Aortic Aneurysm / complications. Cardiac Catheterization / adverse effects. Coronary Disease / etiology
  • [MeSH-minor] Coronary Stenosis / therapy. Dissection. Humans. Iatrogenic Disease. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632532.001).
  • [ISSN] 1876-4738
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Chieffo A, Morici N, Maisano F, Bonizzoni E, Cosgrave J, Montorfano M, Airoldi F, Carlino M, Michev I, Melzi G, Sangiorgi G, Alfieri O, Colombo A: Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation; 2006 May 30;113(21):2542-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience.
  • BACKGROUND: Improvements in results with percutaneous coronary intervention (PCI) with drug-eluting stents (DES) may extend their use in patients with left main coronary artery (LMCA) stenosis.
  • METHODS AND RESULTS: Two hundred forty-nine patients with LMCA stenosis were treated with PCI and DES implantation (n=107) or coronary artery bypass grafting (CABG) (n=142), in a single center, between March 2002 and July 2004.
  • At 1 year, there was no statistical difference in the occurrence of death in PCI versus CABG both for the unadjusted (OR=0.291; 95% CI=0.054 to 1.085; P=0.0710) and adjusted analyses (OR=0.331; 95% CI=0.055 to 1.404; P=0.1673).
  • CONCLUSIONS: At 1 year, in this single-center, retrospective experience, there was no difference in the degree of protection against death, stroke, myocardial infarction, and revascularization between PCI with DES and CABG for LMCA disease.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Stenosis / therapy. Stents
  • [MeSH-minor] Aged. Cerebrovascular Disorders. Humans. Middle Aged. Myocardial Infarction. Pharmaceutical Preparations / administration & dosage. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Circulation. 2006 Nov 7;114(19):e573; author reply e575 [17088469.001]
  • [CommentIn] Circulation. 2006 Nov 7;114(19):e574; author reply e575 [17088470.001]
  • [CommentIn] Circulation. 2006 May 30;113(21):2480-4 [16735688.001]
  • (PMID = 16717151.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


22. Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Nakama Y, Maruhashi T, Kagawa E, Dai K, Matsushita J, Ikenaga H: Therapeutic hypothermia in combination with percutaneous coronary intervention in out-of-hospital cardiac arrest due to left main coronary artery disease. Heart Vessels; 2009 Sep;24(5):376-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic hypothermia in combination with percutaneous coronary intervention in out-of-hospital cardiac arrest due to left main coronary artery disease.
  • Coronary angiography showed 99% narrowing of the left main coronary artery (LMCA), but did not show any disease in the right coronary artery.
  • A bare-metal stent was placed in the LMCA, and postdilated at 20 atmospheres.
  • Subsequently, he was slowly rewarmed at a rate of 0.3 degrees C/h up to 36.0 degrees C.
  • Stent thrombosis did not occur despite the ad hoc loading of antiplatelet drugs.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Heart Arrest / therapy. Hypothermia, Induced. Myocardial Infarction / therapy

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anesthesiology. 1998 Jun;88(6):1579-85 [9637652.001]
  • [Cites] Circulation. 2003 Apr 8;107(13):e91; author reply e91 [12682037.001]
  • [Cites] Heart Vessels. 2008 Jul;23 (4):279-81 [18649059.001]
  • [Cites] J Am Coll Cardiol. 2001 Oct;38(4):1054-60 [11583882.001]
  • [Cites] Thromb Haemost. 2007 Dec;98(6):1266-75 [18064324.001]
  • [Cites] Lancet. 1994 Aug 27;344(8922):563-70 [7914958.001]
  • [Cites] Circulation. 1995 May 1;91(9):2335-44 [7729019.001]
  • [Cites] Crit Care Med. 2004 Mar;32(3):897-9 [15090990.001]
  • [Cites] Heart Vessels. 2007 Mar;22(2):99-103 [17390204.001]
  • [Cites] Chest. 2001 Oct;120(4):1212-7 [11591563.001]
  • [Cites] Circulation. 2001 Oct 2;104(14 ):1609-14 [11581137.001]
  • [Cites] Circulation. 1997 Dec 2;96(11):3867-72 [9403609.001]
  • [Cites] J Am Coll Cardiol. 2004 Sep 1;44(5):e213-310 [15337239.001]
  • [Cites] Ann Thorac Surg. 2000 Aug;70(2 Suppl):S3-8 [10966004.001]
  • [Cites] J Am Coll Cardiol. 2008 Mar 4;51(9):885-92 [18308155.001]
  • [Cites] J Invasive Cardiol. 2004 Nov;16(11):621-5 [15550729.001]
  • [Cites] J Am Coll Cardiol. 2000 Sep;36(3):776-83 [10987599.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):557-63 [11856794.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):549-56 [11856793.001]
  • [Cites] J Am Coll Cardiol. 2000 May;35(6):1543-50 [10807458.001]
  • (PMID = 19784822.001).
  • [ISSN] 1615-2573
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Metals; 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


23. Hu SS, Gao RL, Gao PX, Li LH, Xiong H, Xu B, Yang YJ, Yuan JQ, Zheng Z: [Efficacy of one-stop hybrid revascularization for treatment of unprotected left main coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jan;38(1):23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of one-stop hybrid revascularization for treatment of unprotected left main coronary artery disease].
  • OBJECTIVE: To evaluate the efficacy of one-stop hybrid coronary revascularization [simultaneous minimally invasive direct coronary artery bypass surgery (MIDCAB) and percutaneous coronary intervention (PCI) procedures performed in an enhanced (or called "hybrid") operative unit] for the treatment of unprotected left main coronary artery (ULMCA) disease.
  • MIDCAB procedure for grafting of the left intramammary artery (LIMA) with the left anterior descending (LAD) artery was first performed via lower partial ministernotomy on the beating heart, followed by PCI on the LMCA disease and non-LAD coronary lesions.
  • A total of 25 non-LAD coronary lesions were treated by PCI and 29 stents (27 drug-eluting stents and 2 bare-mental stents) were implanted to 23 lesions and coronary angioplasty was performed in the remaining lesions.
  • LIMA grafts and stents were patent in 5 patients at 1-year follow-up.
  • CONCLUSIONS: Our initial experience demonstrates that one-stop hybrid coronary revascularization provides a reasonable, feasible and safe alternative for selected patients with LMCA diseases.
  • [MeSH-major] Coronary Artery Disease / therapy. Myocardial Revascularization / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angioplasty, Balloon, Coronary. Coronary Artery Bypass, Off-Pump. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398483.001).
  • [ISSN] 0253-3758
  • [Journal-full-title] Zhonghua xin xue guan bing za zhi
  • [ISO-abbreviation] Zhonghua Xin Xue Guan Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


24. Tefferi A: Modern diagnosis and treatment of primary eosinophilia. Acta Haematol; 2005;114(1):52-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern diagnosis and treatment of primary eosinophilia.
  • The recent discovery of an eosinophilia-specific, imatinib-sensitive, karyotypically occult but fluorescence in situ hybridization-apparent molecular lesion in a subset of patients with blood eosinophilia has transformed the diagnostic as well as treatment approach to eosinophilic disorders.
  • Primary (i.e. nonreactive) eosinophilia is considered either "clonal" or "idiopathic" based on the presence or absence, respectively, of either a molecular or bone marrow histological evidence for a myeloid neoplasm.
  • Clonal eosinophilia might accompany a spectrum of clinicopathological entities, the minority of whom are molecularly characterized; Fip1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA(+)) systemic mastocytosis, platelet-derived growth factor receptor beta (PDGFRB)-rearranged atypical myeloproliferative disorder, chronic myeloid leukemia, and the 8p11 syndrome that is associated with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
  • Hypereosinophilic syndrome (HES) is a subcategory of idiopathic eosinophilia and is characterized by an absolute eosinophil count of > or =1.5 x 10(9)/l for at least 6 months as well as eosinophil-mediated tissue damage.
  • At present, a working diagnosis of primary eosinophilia mandates a bone marrow examination, karyotype analysis, and additional molecular studies in order to provide the patient with accurate prognostic information as well as select appropriate therapy.
  • Allogeneic transplantation offers a viable treatment option for drug-refractory cases.
  • [MeSH-major] Bone Marrow / pathology. Hypereosinophilic Syndrome / diagnosis. Hypereosinophilic Syndrome / therapy. Mastocytosis, Systemic / diagnosis. Mastocytosis, Systemic / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Oncogene Proteins, Fusion. Receptor, Platelet-Derived Growth Factor alpha / analysis. Stem Cell Transplantation. Transplantation, Homologous. mRNA Cleavage and Polyadenylation Factors / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15995325.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / mRNA Cleavage and Polyadenylation Factors; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 142
  •  go-up   go-down


25. Martínez-Ríos MA, Méndez-Ortíz A, Gaspar J, Barragán-García R, Fernández-de-la-Reguera G, González-Quesada CJ: Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in a patient with cardiac allograft vasculopathy. Arch Cardiol Mex; 2008 Oct-Dec;78(4):407-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in a patient with cardiac allograft vasculopathy.
  • After the first year of transplantation, allograft coronary artery disease (ACAD) is the second main cause of death.
  • We present a case of successful stenting of the left main coronary artery (LMCA) in a patient with ACAD.
  • Coronary angiogram showed a severe stenosis in the proximal segment of the LMCA; we performed stenting with a paclitaxel-eluting stent (PES).
  • Our report suggests the efficacy of PES as ACAD treatment of the unprotected LMCA.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Coronary Stenosis / therapy. Drug-Eluting Stents. Heart Transplantation / adverse effects. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205549.001).
  • [ISSN] 1405-9940
  • [Journal-full-title] Archivos de cardiología de México
  • [ISO-abbreviation] Arch Cardiol Mex
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Gupta S, Gupta BM: Coronary artery bypass surgery or drug eluting stent for unprotected left main coronary artery disease. J Assoc Physicians India; 2007 Apr;55:287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coronary artery bypass surgery or drug eluting stent for unprotected left main coronary artery disease.
  • Coronary artery bypass surgery (CABG) is the treatment of choice in unprotected left main coronary artery disease (ULMCA).
  • However drug eluting stent (DES) implantations in ULMCA have ushered a revolution in the field of percutaneous coronary interventions (PCI) for left main coronary artery (LMCA) by reducing peri-procedural mortality and incidence of major adverse cardiac events (MACE).
  • [MeSH-major] Coronary Artery Bypass. Coronary Disease / surgery. Stents
  • [MeSH-minor] Coronary Restenosis / prevention & control. Drug Delivery Systems. Humans. Vascular Patency

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694790.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 18
  •  go-up   go-down


27. Han Y, Wang S, Jing Q, Li Y, Liu H, Ma Y, Wang Z, Wang D, Luan B, Wang G, Chen T: Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease. Am J Cardiol; 2009 Jan 15;103(2):194-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease.
  • The use of paclitaxel-eluting stents (PES) for the treatment of unprotected left main coronary artery (LMCA) disease is controversial.
  • Between January 2003 and December 2006, a total of 287 patients undergoing percutaneous coronary intervention for LMCA lesions were consecutively registered.
  • PES recipients had distal left main bifurcation lesions more frequently compared with BMS recipients (72 vs 42%, p<0.01).
  • Angiographic follow-up was performed in 61% and 59% of PES and BMS recipients, respectively.
  • In conclusion, PES implantation provides a safe, effective therapy for unprotected LMCA disease and decreases the risk of major adverse cardiac events compared with BMS at a mean follow-up of 35 months.
  • [MeSH-major] Coronary Artery Disease / therapy. Drug-Eluting Stents. Paclitaxel / administration & dosage. Stents. Tubulin Modulators / administration & dosage

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121435.001).
  • [ISSN] 1879-1913
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Park SJ, Kim YH: Percutaneous coronary intervention for unprotected left main coronary artery stenosis. World J Cardiol; 2010 Apr 26;2(4):78-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous coronary intervention for unprotected left main coronary artery stenosis.
  • Hemodynamically significant left main coronary artery stenosis (LMCA) is found in around 4% of diagnostic coronary angiograms and is known as unprotected LMCA stenosis if the left coronary artery and left circumflex artery has no previous patent grafts.
  • Previous randomized studies have demonstrated a significant reduction in mortality when revascularization by coronary artery bypass graft (CABG) surgery was undertaken compared with medical treatment.
  • However, with the advent of drug-eluting stents (DES), the long term outcomes of PCI with DES to treat unprotected LMCA stenoses have been acceptable.
  • Therefore, apart from the current guidelines, PCI for treatment of unprotected LMCA stenosis is often undertaken in individuals who are at a very high risk of CABG or refuse to undergo a sternotomy.
  • Future randomized studies comparing CABG vs PCI using DES for treatment of unprotected LMCA stenosis would be a great advance in clinical knowledge for the adoption of appropriate treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160702.001).
  • [ISSN] 1949-8462
  • [Journal-full-title] World journal of cardiology
  • [ISO-abbreviation] World J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2998877
  • [Keywords] NOTNLM ; Bypass surgery / Left main / Prognosis / Restenosis / Stent
  •  go-up   go-down


29. Topaz O, Polkampally PR, Mohanty PK, Rizk M, Bangs J, Bernardo NL: Excimer laser debulking for percutaneous coronary intervention in left main coronary artery disease. Lasers Med Sci; 2009 Nov;24(6):955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excimer laser debulking for percutaneous coronary intervention in left main coronary artery disease.
  • Excimer laser has been successfully applied to complex atherosclerotic plaques in acute coronary syndromes; however, its role in debulking in left main coronary artery disease has not been fully explored.
  • Details of a series of 20 patients who underwent excimer laser revascularization of a spectrum of left main coronary artery lesions are presented.
  • The left main coronary artery was characterized as protected, semi-protected, poorly protected, or unprotected, depending on the presence or absence of patent bypass grafts to the left anterior descending (LAD) and circumflex (CX) arteries.
  • A fully protected left main coronary artery (LMCA) was present in only 20% of the patients.
  • The target lesions included 11(55%) distal LMCA stenoses, six (30%) ostial stenoses, and one (5%) mid-portion lesions.
  • Two (10%) patients had in-stent re-stenosis of the entire length of the LMCA.
  • Successful LMCA intervention was performed in 19 (95%) patients, while in-hospital complications occurred in only one (5%) patient.
  • Subacute/late stent thrombosis developed 3 months after the procedure in one patient, and two patients died from non-cardiac causes during follow-up.
  • Lesions in LMCAs can be revascularized in selected patients by laser debulking and adjunct stenting.
  • Inadequate protection by bypass grafts and decreased left ventricular function do not contradict utilization of excimer laser.
  • Small laser catheters and high energy levels are required during laser debulking of stenoses of left main coronary arteries.
  • [MeSH-major] Angioplasty, Balloon, Laser-Assisted / methods. Coronary Artery Disease / therapy. Lasers, Excimer / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Angioplasty, Balloon, Coronary / methods. Coronary Angiography. Drug-Eluting Stents. Female. Humans. Male. Middle Aged. Retrospective Studies. Stents. Thrombolytic Therapy

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Laser Med Surg. 2001 Feb;19(1):9-14 [11547819.001]
  • [Cites] Cardiovasc Revasc Med. 2007 Apr-Jun;8(2):84-9 [17574165.001]
  • [Cites] Thromb Haemost. 2001 Oct;86(4):1087-93 [11686328.001]
  • [Cites] Am J Cardiol. 2003 Apr 1;91(7):797-802 [12667563.001]
  • [Cites] Semin Interv Cardiol. 1996 Jun;1(2):135-41 [9552504.001]
  • [Cites] Am J Cardiol. 2008 Jan 15;101(2):169-72 [18178401.001]
  • [Cites] Circulation. 1993 Nov;88(5 Pt 1):2049-57 [8222098.001]
  • [Cites] Catheter Cardiovasc Interv. 2004 Jun;62(2):155-61 [15170703.001]
  • [Cites] Am J Cardiol. 2008 Jan 1;101(1):75-81 [18157969.001]
  • [Cites] J Am Coll Cardiol. 2007 Aug 14;50(7):573-83 [17692740.001]
  • [Cites] Circulation. 2001 Oct 2;104(14 ):1609-14 [11581137.001]
  • [Cites] Lasers Surg Med. 2001;29(2):185-92 [11553909.001]
  • [Cites] Tex Heart Inst J. 2007;34(4):479-84 [18172536.001]
  • [Cites] J Invasive Cardiol. 2004 Apr;16(4):177-80 [15152140.001]
  • [Cites] Lasers Med Sci. 2001;16(2):72-7 [11484757.001]
  • [Cites] Br Heart J. 1993 Mar;69(3):255-9 [8461226.001]
  • [Cites] Cardiology. 1996 Sep-Oct;87(5):384-91 [8894258.001]
  • [Cites] J Thromb Thrombolysis. 2006 Dec;22(3):165-7 [17111201.001]
  • [Cites] J Am Coll Cardiol. 1998 Jan;31(1):37-42 [9426015.001]
  • [Cites] Circulation. 1995 Dec 15;92 (12 ):3408-14 [8521561.001]
  • [Cites] Lasers Med Sci. 1999 Jun;14(2):123-8 [24519167.001]
  • [Cites] Am J Cardiol. 2001 Apr 1;87(7):849-55 [11274939.001]
  • [Cites] J Interv Cardiol. 1995 Dec;8(6):633-8 [10159753.001]
  • [Cites] Am J Cardiol. 2004 Mar 15;93(6):694-701 [15019871.001]
  • [Cites] J Am Coll Cardiol. 2000 May;35(6):1543-50 [10807458.001]
  • [Cites] Cathet Cardiovasc Diagn. 1994 Dec;33(4):317-22 [7889549.001]
  • (PMID = 19238505.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Cherradi R, Ouldzein H, Zouaoui W, Elbaz M, Puel J, Carrié D: Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients). Arch Cardiovasc Dis; 2008 Jan;101(1):11-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients).
  • BACKGROUND: After coronary stenting with drug eluting stents, long-term clinical outcome of unprotected left main coronary artery disease is unknown, even large scale registries or randomised trials with coronary artery bypass graft are ongoing.
  • AIMS: To report clinical and angiographic results of paclitaxel-eluting stent implantation for left main coronary artery stenosis (a series of 101 consecutive patients).
  • METHODS: This report is a prospective study performed to evaluate the immediate and mid-term clinical and angiographic outcomes of patients undergoing paclitaxel-eluting stent (PES) implantation for unprotected left main coronary artery (LMCA) stenosis.
  • From January 2004 to December 2005, 101 consecutive patients were stented with paclitaxel-eluting stents (the provisional T stenting technique followed by Kissing balloon for distal left main vessel disease).
  • Distal left main trunk lesions were present in 87.1% of cases.
  • Three-vessel disease represented 7% of cases.
  • CONCLUSION: Paclitaxel-eluting stent implantation for unprotected left main coronary disease appears to be safe with high procedural success rate and a low re-stenosis rate at six month-follow-up.
  • [MeSH-major] Acute Coronary Syndrome. Angioplasty, Balloon, Coronary / instrumentation. Cardiovascular Agents / administration & dosage. Coronary Angiography. Coronary Stenosis. Drug-Eluting Stents. Paclitaxel / administration & dosage

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Cardiovasc Dis. 2008 Jan;101(1):7-8 [18391865.001]
  • (PMID = 18391867.001).
  • [ISSN] 1875-2136
  • [Journal-full-title] Archives of cardiovascular diseases
  • [ISO-abbreviation] Arch Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 0 / Platelet Aggregation Inhibitors; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Ghenim R, Roncalli J, Tidjane AM, Bongard V, Ziani A, Boudou N, Dumonteil N, Marcheix B, Léobon B, Carrié D: One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged &gt;or=75 years). J Interv Cardiol; 2009 Dec;22(6):520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >or=75 years).
  • PURPOSE: The present observational study compares in-hospital and 12-month clinical outcomes in elderly patients with unprotected left main coronary artery disease treated either with coronary artery bypass grafting or drug-eluting stent.
  • METHODS: From January 2004 to December 2007, 211 patients (pts) with unprotected left main coronary artery (ULMCA) stenosis, aged 75 or older, underwent coronary revascularization either with coronary artery bypass graft (CABG) (106 pts) or drug-eluting stent (DES) (105 pts).
  • The PCI group was significantly associated with older age, dyslipidemia, history of cancer, high Euroscore, elevated creatininemia, single-vessel disease, fewer chronic occlusions of the left anterior descending artery, and more LMCA stenosis >or=70%.
  • The multivariate logistic regression analysis was adjusted for age, diabetes, left ventricular ejection fraction, Euroscore, and plasma creatininemia and stratified on the score of propensity to be treated with PCI.
  • In the subgroup below median propensity score, the adjusted odds ratio for 1-year MACCE was OR = 0.91 (95% confidence interval: 0.14 to 5.98; P = 0.924) whereas OR was 0.16 (0.04-0.69; P = 0.013) in the subgroup above median propensity score.
  • CONCLUSIONS: In patients with a high probability of being treated with PCI (older age, high Euroscore, high creatininemia, single-vessel disease, ...), the 1-year risk of MACCE was significantly lower in PCI- than in CABG-treated subjects.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Artery Disease / surgery. Drug-Eluting Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Anticoagulants / therapeutic use. Aspirin / therapeutic use. Confidence Intervals. Female. Heparin / therapeutic use. Humans. Logistic Models. Male. Multivariate Analysis. Odds Ratio. Platelet Aggregation Inhibitors / therapeutic use. Prospective Studies. Stroke Volume. Ticlopidine / analogs & derivatives. Ticlopidine / therapeutic use. Time Factors. Ventricular Function, Left

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735473.001).
  • [ISSN] 1540-8183
  • [Journal-full-title] Journal of interventional cardiology
  • [ISO-abbreviation] J Interv Cardiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Platelet Aggregation Inhibitors; 9005-49-6 / Heparin; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; R16CO5Y76E / Aspirin
  •  go-up   go-down


32. Furuichi S, Sangiorgi GM, Palloshi A, Godino C, Airoldi F, Montorfano M, Chieffo A, Michev I, Carlino M, Colombo A: Drug-eluting stent implantation in coronary trifurcation lesions. J Invasive Cardiol; 2007 Apr;19(4):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-eluting stent implantation in coronary trifurcation lesions.
  • OBJECTIVE: To evaluate the mid-term clinical and angiographic outcome of drug-eluting stent (DES) implantation in trifurcation lesions.
  • RESULTS: A total of 15 consecutive patients undergoing percutaneous coronary intervention with DES in de novo trifurcation lesions were identified.
  • Lesions were located as follows: 13 (86.7%) at the distal left main coronary artery (LMCA) comprising the left anterior descending artery (LAD), the left circumflex artery (LCX) and an intermediate branch; 1 between the LAD, diagonal, and septal branches; and 1 between the LCX, obtuse marginal and posterior lateral branches.
  • TLR occurred in 3 patients (20%) with LMCA lesions.
  • CONCLUSION: Most trifurcation lesions were found in the distal LMCA.
  • [MeSH-major] Coronary Disease / therapy. Prosthesis Implantation / methods. Stents
  • [MeSH-minor] Aged. Angioplasty, Balloon, Coronary. Coronary Angiography. Coronary Restenosis / epidemiology. Female. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invasive Cardiol. 2007 Jun;19(6):284; author reply 284-5 [17541134.001]
  • (PMID = 17404400.001).
  • [ISSN] 1557-2501
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


33. Park SJ, Kim YH: Percutaneous coronary intervention as an alternative to bypass surgery for unprotected LMCA stenosis. Expert Rev Cardiovasc Ther; 2008 Sep;6(8):1107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous coronary intervention as an alternative to bypass surgery for unprotected LMCA stenosis.
  • Hemodynamically significant left main coronary artery (LMCA) stenosis is found in approximately 4% of diagnostic coronary angiograms and is known as unprotected LMCA stenosis if the left coronary artery and left circumflex artery have no patent previous grafts.
  • Previous randomized studies have demonstrated a significant reduction in mortality when revascularization by coronary artery bypass graft (CABG) surgery was undertaken compared with medical treatment.
  • However, with the advent of drug-eluting stents (DES), the long-term outcomes of PCI with DES to treat unprotected LMCA stenoses have been reported to be acceptable.
  • Therefore, apart from the current guidelines, PCI for unprotected LMCA stenosis in many countries is often undertaken in individuals who are at very high risk of CABG or refuse to undergo a sternotomy.
  • Future randomized studies comparing CABG versus PCI using DES for treatment of unprotected LMCA stenosis would be a great advance in the clinical knowledge of adopting appropriate treatments.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Stenosis / therapy. Stents
  • [MeSH-minor] Coronary Restenosis / epidemiology. Coronary Restenosis / prevention & control. Drug-Eluting Stents. Humans. Platelet Aggregation Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Registries. Treatment Outcome. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793113.001).
  • [ISSN] 1744-8344
  • [Journal-full-title] Expert review of cardiovascular therapy
  • [ISO-abbreviation] Expert Rev Cardiovasc Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors
  • [Number-of-references] 39
  •  go-up   go-down


34. Tyczyński P, Witkowski A, Chojnowska L, Litwiński P, Dabrowski M, Ryzyłło W: [Angioplasty of the unprotected left main coronary artery stenosis with standby cardiopulmonary support--a case report]. Kardiol Pol; 2007 Mar;65(3):286-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioplasty of the unprotected left main coronary artery stenosis with standby cardiopulmonary support--a case report].
  • Stenosis of the unprotected left main coronary artery (LMCA) is a classical indication for coronary artery bypass graft surgery (CABG).
  • Percutaneous coronary intervention (PCI) of LMCA may be an alternative to surgical treatment if atherosclerosis of distal segments is very advanced.
  • The ongoing Syntax trial will clarify whether angioplasty of LMCA with drug-eluting stents can be equivalent to CABG.
  • We present a case of a patient with occluded right coronary artery, severe stenoses of the LMCA, left anterior descending artery and left circumflex artery, and poor left ventricular ejection fraction in whom PCI for stenosis of unprotected LMCA with standby cardiopulmonary support was performed.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Cardiopulmonary Bypass. Coronary Artery Bypass. Coronary Artery Disease / therapy. Coronary Stenosis / therapy


35. Lindsey JB, Brilakis ES, Banerjee S: Acute coronary syndrome due to extrinsic compression of the left main coronary artery in a patient with severe pulmonary hypertension: successful treatment with percutaneous coronary intervention. Cardiovasc Revasc Med; 2008 Jan-Mar;9(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute coronary syndrome due to extrinsic compression of the left main coronary artery in a patient with severe pulmonary hypertension: successful treatment with percutaneous coronary intervention.
  • A patient with severe pulmonary (arterial) hypertension (PH) presented with a non-ST segment elevation myocardial infarction and recurrent angina at rest.
  • Coronary angiography showed severe ostial left main coronary artery (LMCA) stenosis; coronary arteries were otherwise normal.
  • Intravascular ultrasonography (IVUS) showed deformation of the LMCA due to extrinsic compression from a markedly dilated main pulmonary artery, which was confirmed by cardiac computed tomography.
  • The LMCA was successfully stented using a paclitaxel-eluting stent resulting in complete resolution of angina.
  • Extrinsic compression of the LMCA should be considered in patients with severe PH and angina; IVUS may aid in the diagnosis.
  • [MeSH-major] Acute Coronary Syndrome / therapy. Angioplasty, Balloon, Coronary. Coronary Stenosis / therapy. Hypertension, Pulmonary / complications. Pulmonary Artery / pathology
  • [MeSH-minor] Angina Pectoris / etiology. Angina Pectoris / therapy. Cardiovascular Agents / administration & dosage. Coronary Angiography. Dilatation, Pathologic. Drug-Eluting Stents. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Platelet Aggregation Inhibitors / therapeutic use. Severity of Illness Index. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206638.001).
  • [ISSN] 1878-0938
  • [Journal-full-title] Cardiovascular revascularization medicine : including molecular interventions
  • [ISO-abbreviation] Cardiovasc Revasc Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 0 / Platelet Aggregation Inhibitors; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


36. Han YL, Wang SL, Jin QM, Liu HW, Ma YY, Wang ZL, Wang DM, Luan B, Wang G: Efficacy of stenting for unprotected left main coronary artery disease in 297 patients. Chin Med J (Engl); 2006 Apr 5;119(7):544-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of stenting for unprotected left main coronary artery disease in 297 patients.
  • BACKGROUND: Angioplasty in the unprotected left main coronary artery (LMCA) has been controversial.
  • This study aims to evaluate the safety and clinical effectiveness of stenting, including bare metal stent and drug eluting stent (DES), for treatment of unprotected LMCA disease.
  • METHODS: Between September 1997 and December 2005, a total of 297 consecutive patients underwent percutanous coronary intervention (PCI) on LMCA lesions in our hospital.
  • Stents failed to be implanted after balloon predilation in two patients, who received coronary artery bypass graft (CABG) successfully.
  • Bifurcation techniques for distal LMCA executed in 206 patients (69.4%, 206/297), included crossover stenting in 156 (75.7%), T stenting in 4 (1.9%), provisional T stenting in 28 (13.6%), kissing stenting in 5 (2.4%) and stent crushing in 13 (6.3%) patients.
  • Besides, 2 (0.7%) developed subacute thrombosis (SAT) and 16 (5.4%) performed target lesion revascularization (TLR).
  • CONCLUSIONS: As new PCI strategies and intervention devices such as DES are developed, coronary stenting, which might have brought better in-hospital and long-term outcomes than CABG, are proved to be technically successful and can be safely applied for the treatment of LMCA lesions in the experienced center for coronary intervention.
  • [MeSH-major] Coronary Disease / therapy. Stents

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620694.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Tanigawa J, Sutaria N, Goktekin O, Di Mario C: Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era. J Interv Cardiol; 2005 Dec;18(6):455-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era.
  • Coronary angiography is often inadequate for estimating the severity of ambiguous left main coronary artery (LMCA) stenoses.
  • For patients requiring LMCA revascularization, coronary artery bypass graft (CABG) surgery has been gold standard for decades.
  • LMCA stenosis remains one of the few serious challenges for the interventional cardiologists and, in the bare metal stent era, the long-term results were not sufficient to replace CABG surgery, mainly because of the high restenosis rate.
  • Drug-eluting stents (DES) have dramatically reduced the restenosis rate and early results in small series (approximately 300 patients in total) treated with DES in LMCA have been encouraging, especially for lesions at the ostium and in the left main shaft.
  • Before changes are made in the guidelines for treatment, we must wait for a refinement in the technique and stent design used for bifurcational left main lesion and the results of randomized, specific multicenter studies (SYNTAX trial).
  • It is likely that, for selected patients, LMCA stenosis will be regarded as an indication for PCI.
  • [MeSH-major] Blood Vessel Prosthesis Implantation. Coronary Stenosis / drug therapy. Drug Delivery Systems. Stents
  • [MeSH-minor] Angioplasty, Balloon, Coronary. Atherectomy, Coronary. Coronary Artery Bypass. Coronary Restenosis / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Sirolimus / administration & dosage

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (J Interven Cardiol 2005;18:455-465).
  • (PMID = 16336426.001).
  • [ISSN] 0896-4327
  • [Journal-full-title] Journal of interventional cardiology
  • [ISO-abbreviation] J Interv Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 60
  •  go-up   go-down


38. Cholteesupachai J, Udayachalerm W, Srimahachota S, Buddhari W, Chaipromprasit J, Songmuang SB, Suithichaiyakul T: In-hospital and mid-term outcomes of stent implantation in patients with protected and unprotected left main coronary artery disease; King Chulalongkorn Memorial Hospital experiences. J Med Assoc Thai; 2009 Jun;92(6):755-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In-hospital and mid-term outcomes of stent implantation in patients with protected and unprotected left main coronary artery disease; King Chulalongkorn Memorial Hospital experiences.
  • BACKGROUND: Left Main Coronary Artery (LMCA) disease is now uniformly treated with coronary artery by pass grafting (CABG).
  • However some patients with LMCA disease did not receive CABG because of high operative risks as well as those who refused CABG Recent studies demonstrated the feasibility of stenting for LM stenosis, although data remain limited.
  • OBJECTIVE: To evaluate in-hospital and mid-term outcomes of using bare metal stent (BMS) and drug eluting stent (DES) in protected and unprotected left main coronary artery disease at King Chulalongkorn Memorial Hospital.
  • The authors reviewed the outcomes of patients who underwent percutaneous coronary intervention on left main coronary artery lesions in our hospital from July 2000 to August 2007.
  • RESULTS: In eight years the authors reviewed 64 consecutive protected and unprotected LMCA patients who underwent PCI with stent placement.
  • Altogether left main coronary artery stents were successfully deployed in all patients.
  • Bifurcation technique for distal left main coronary artery was executed in 32 patients (50%), included single stent in 62 (97%), two stents in 2(3%).
  • CONCLUSION: Stent Implantation was technically feasible and safely applied for the treatment ofprotected and unprotected left main coronary artery lesions in patients, with acceptable in-hospital and mid-term outcomes.
  • More randomized and controlled clinical trials are needed to confirm the long-term effects of stents for LMCA disease.
  • [MeSH-major] Coronary Artery Disease / therapy. Coronary Restenosis / prevention & control. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Coronary Angiography. Drug-Eluting Stents. Feasibility Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530580.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


39. Seung KB, Kim YH, Park DW, Lee BK, Lee CW, Hong MK, Kim PJ, Chung WS, Tahk SJ, Park SW, Park SJ: Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol; 2005 Sep 6;46(5):787-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance.
  • OBJECTIVES: This study was designed to evaluate the clinical and angiographic outcomes of sirolimus-eluting stent (SES) implantation for ostial left anterior descending (LAD) lesions compared with bare-metal stent (BMS) implantation.
  • In the SES group, for complete lesion coverage, stent positioning was intentionally extended into the distal left main coronary artery (LMCA) in 23 patients (34%) with intermediate LMCA narrowing.
  • In the SES group, there were no restenoses in cases with LMCA coverage, compared with three restenoses (7.9%) in cases with precise stent positioning (p = NS).
  • This finding may be associated with reduced neointimal hyperplasia and complete lesion coverage.
  • [MeSH-major] Blood Vessel Prosthesis Implantation / methods. Coronary Stenosis / surgery. Immunosuppressive Agents / administration & dosage. Sirolimus / therapeutic use. Stents
  • [MeSH-minor] Coronary Angiography. Coronary Restenosis / prevention & control. Delayed-Action Preparations. Drug Delivery Systems. Female. Humans. Male. Middle Aged. Prospective Studies

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139126.001).
  • [ISSN] 0735-1097
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


40. Kim U, Park JS, Seol SH, Yang TH, Kim SM, Kim DK, Kim DI, Kim DS, Lee WJ, Lee SH, Hong GR, Shin DG, Kim YJ, Shim BS, Cho YK, Kim HS, Nam CW, Hur SH, Kim KB, Kim YN: Two-year outcomes of the sirolimus-eluting stent according to unprotected left main lesion. Clin Cardiol; 2009 Jun;32(6):332-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-year outcomes of the sirolimus-eluting stent according to unprotected left main lesion.
  • BACKGROUND: The data of long-term outcomes of sirolimus-eluting stent (SES) according to lesion location of unprotected left main coronary artery (LMCA) is scarce.
  • HYPOTHESIS: The purpose of this study was to evaluate the long-term outcomes after implantation of the SES in LMCA.
  • METHODS: A total of 84 patients (51 males) who had undergone SES implantation for the treatment of native LMCA stenosis were enrolled.
  • Although angiographic success and in-hospital MACE rates were similar in both groups with 1 cardiac death due to acute stent thrombosis in group 2, at 2-year follow-up, the MACE rate was significantly higher in group 2 than in group 1 at 2 years (22.2% vs 2.6%, respectively, P = 0.008).
  • CONCLUSIONS: Interventional treatment using SES in left main lesions showed favorable short-term and long-term outcomes in selected patients with lesion location being an important determinant of clinical and angiographic outcomes.
  • [MeSH-major] Angioplasty, Balloon, Coronary / instrumentation. Cardiovascular Agents / administration & dosage. Cardiovascular Diseases / prevention & control. Coronary Stenosis / therapy. Drug-Eluting Stents. Sirolimus / administration & dosage

  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley Periodicals, Inc.
  • (PMID = 19569064.001).
  • [ISSN] 1932-8737
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


41. Kang SH, Park KH, Choi DJ, Park KW, Chung WY, Lim C, Kim KB, Kim HS: Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry). Am J Cardiol; 2010 Feb 1;105(3):343-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry).
  • Recent studies have suggested that percutaneous coronary intervention (PCI) in patients with unprotected left main coronary artery (LMCA) disease renders outcomes comparable to those from coronary artery bypass grafting (CABG).
  • We compared the clinical outcomes of patients with unprotected LMCA disease who had undergone PCI with drug-eluting stents or CABG.
  • We identified 462 patients who were treated from January 2003 to December 2006 for unprotected LMCA or LMCA-equivalent disease: 257 had undergone CABG and 205 had undergone PCI with drug-eluting stents.
  • In conclusion, PCI with drug-eluting stents showed a safety profile comparable to that of CABG in patients with unprotected LMCA disease.
  • [MeSH-major] Coronary Artery Bypass. Coronary Artery Disease / surgery. Drug-Eluting Stents

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20102946.001).
  • [ISSN] 1879-1913
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Barragan P, Fajadet J, Sheiban I, Serruys P, Colombo A, Seabra-Gomes R, Goy JJ, Cook S, Rubino P, Lefèvre T: Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year. EuroIntervention; 2008 Aug;4(2):262-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year.
  • AIMS: Recent studies of drug-eluting stents for unprotected left main coronary artery (LMCA) disease have been encouraging.
  • METHODS AND RESULTS: This retrospective study included 228 consecutive patients (mean age = 68 +/- 11 years, 80.6% men, 26.3% diabetics) who underwent implantation of SES for de novo LMCA stenoses.
  • The main objective of this study was to measure the rate of major adverse cardiac events (MACE), including death, myocardial infarction and target lesion revascularisation (TLR) at 12 months.
  • CONCLUSIONS: SES implants in high-risk patients with LMCA stenoses were associated with a low 1-year MACE rate.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Immunosuppressive Agents / administration & dosage. Sirolimus / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Coronary Circulation. Coronary Vessels / pathology. Drug-Eluting Stents / statistics & numerical data. Female. Follow-Up Studies. Humans. Inpatients / statistics & numerical data. Male. Middle Aged. Outpatients / statistics & numerical data. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110793.001).
  • [ISSN] 1774-024X
  • [Journal-full-title] EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • [ISO-abbreviation] EuroIntervention
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


43. Park SJ: Is stenting a preferred option for unprotected left main coronary artery disease in the drug-eluting stent era? Indian Heart J; 2007 Mar-Apr;59(2 Suppl B):B105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is stenting a preferred option for unprotected left main coronary artery disease in the drug-eluting stent era?
  • Coronary artery bypass graft (CABG) has been the established treatment for left main coronary artery (LMCA) disease.
  • LMCA disease has been considered to be a challenge for interventional cardiologist for more than 25 years.
  • The early experience with drug-eluting stent (DES) in unprotected LMCA reveals reduced rates of restenosis and associated clinical outcomes when compared with patients who were treated with BMS.
  • However, up to now, effectiveness of DES is not enough to replace CABG in LMCA revascularization.
  • Based on these trials, it is likely that, for selected patients, DES may be regarded as a preferred revascularization strategy for LMCA disease.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Disease / therapy. Coronary Restenosis / prevention & control. Drug-Eluting Stents
  • [MeSH-minor] Coronary Artery Bypass. Hospital Mortality. Humans. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153426.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 39
  •  go-up   go-down


44. Lee JH, Kim EM, Ahn KT, Kim MS, Kim KS, Jung IS, Park JH, Choi SW, Seong IW, Jeong JO: Significant left main coronary artery disease from iatrogenic dissection during coronary angiography. Int J Cardiol; 2010 Jan 21;138(2):e35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant left main coronary artery disease from iatrogenic dissection during coronary angiography.
  • Though atherosclerotic obstruction is the major cause of the obstructive left main coronary artery (LMCA) disease, it can be associated with iatrogenic dissection during coronary angiography.
  • Here we report a case with severe LMCA stenosis due to catheter induced dissection in a 77-year-old man which was detected 9 months later.
  • By careful review of the angiogram had taken at 9 months ago, the LMCA was injured by the diagnostic left Judkin's catheter during the first coronary angiography.
  • The patient was successfully treated with two drug-eluting stents by crushing technique and discharged without further complication.
  • [MeSH-major] Coronary Angiography / adverse effects. Coronary Artery Disease / etiology. Coronary Artery Disease / radiography. Coronary Vessels / injuries. Iatrogenic Disease
  • [MeSH-minor] Aged. Angioplasty, Balloon, Coronary. Drug-Eluting Stents. Humans. Male

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.
  • [CommentIn] Int J Cardiol. 2010 Oct 8;144(2):334-7 [19332358.001]
  • (PMID = 18723232.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Gao RL, Xu B, Chen JL, Yang YJ, Qiao SB, Li JJ, Qin XW, Yao M, Liu HB, Wu YJ, Yuan JQ, Chen J: Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation. Am Heart J; 2008 Mar;155(3):553-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.
  • BACKGROUND: The efficacy and safety of drug-eluting stent (DES) implantation for unprotected left main coronary artery (LMCA) disease remain to be established in different clinical settings.
  • METHODS: Elective DES implantation for unprotected LMCA stenosis was performed in 220 patients at the Fu Wai Hospital, China, from April 2003 to February 2006.
  • Data derived from the latter group were compared with those derived from 224 patients treated with bare-metal stents (BMSs) before March 2003 in a Chinese registry of unprotected LMCA stenting.
  • RESULTS: Compared with the historical BMS control group, the DES group had more multivessel disease and underwent more bifurcation stenting.
  • The inhospital major adverse cardiac events were significantly higher in the DES than in the BMS recipients (4.1% vs 0.9%, P = .030) because of more complex lesions and procedures in the DES group.
  • Angiographic follow-up was performed in 46.4% of DES and 45.7% of BMS recipients, respectively; and the binary restenosis rate was significantly lower in the DES versus the BMS control group (16.7% vs 31.4%, P = .014).
  • CONCLUSIONS: Based on this comparison with a historical control, DES implantation for unprotected LMCA appears safe in selected patients and might be more effective in preventing major adverse cardiac events compared with BMS implantation over a mean follow-up period of 15 months.
  • [MeSH-major] Blood Vessel Prosthesis Implantation / instrumentation. Coated Materials, Biocompatible. Coronary Disease / surgery. Metals. Myocardial Revascularization / methods. Stents
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. China / epidemiology. Coronary Angiography. Coronary Restenosis / epidemiology. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / pharmacology. Incidence. Male. Middle Aged. Paclitaxel / pharmacology. Retrospective Studies. Sirolimus / pharmacology. Time Factors. Treatment Outcome. Ultrasonography, Interventional

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294496.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coated Materials, Biocompatible; 0 / Immunosuppressive Agents; 0 / Metals; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


46. Park SJ, Park DW: Drug-eluting stents for left main coronary artery stenosis: case selection and technical issues. Am Heart Hosp J; 2008;6(1):21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-eluting stents for left main coronary artery stenosis: case selection and technical issues.
  • The use of coronary stents for the treatment of left main coronary artery (LMCA) stenosis is feasible and is associated with a high rate of procedural success and low rates of early and late complications, such as death, myocardial infarction, and stent thrombosis, in low-risk patient populations.
  • Patients at high risk for coronary artery bypass grafting (CABG), however, have reduced event-free survival after stenting.
  • Compared with bare-metal stents for LMCA disease, the subsequent rate of target lesion revascularization appears to be diminished by use of drug-eluting stents (DESs), with similar or enhanced survival and freedom from myocardial infarction.
  • Results of prospective randomized trials comparing the use of DESs with CABG may be needed to ascertain whether DESs could be a reasonable alternative for patients with LMCA disease.
  • [MeSH-major] Coronary Stenosis / surgery. Coronary Vessels / surgery. Drug-Eluting Stents
  • [MeSH-minor] Coronary Artery Bypass. Humans. Korea. Outcome Assessment (Health Care)

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18256554.001).
  • [ISSN] 1541-9215
  • [Journal-full-title] The American heart hospital journal
  • [ISO-abbreviation] Am Heart Hosp J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


47. Mäkikallio TH, Niemelä M, Kervinen K, Jokinen V, Laukkanen J, Ylitalo I, Tulppo MP, Juvonen J, Huikuri HV: Coronary angioplasty in drug eluting stent era for the treatment of unprotected left main stenosis compared to coronary artery bypass grafting. Ann Med; 2008;40(6):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coronary angioplasty in drug eluting stent era for the treatment of unprotected left main stenosis compared to coronary artery bypass grafting.
  • BACKGROUND: Improved outcomes of percutaneous coronary interventions (PCI) with drug-eluting stents (DES) have resulted in their expanded use for left main coronary artery (LMCA) stenosis.
  • AIM: We compared outcomes of patients undergoing PCI for unprotected LMCA stenosis and patients treated by coronary artery bypass grafting (CABG).
  • All subjects treated with revascularization of LMCA stenosis (n = 287) were included and followed up for a mean of 12+6 months.
  • The most significant independent predictor of mortality was reduced left ventricular systolic function (hazard ratio 14.9, 95% CI 5.5-40.0, P < 0.001).
  • CONCLUSIONS: PCI with DES for selected LMCA disease patients results in short- and midterm outcomes comparable to results of CABG in general.
  • PCI is a viable therapeutic option in selected patients with LMCA stenosis.
  • [MeSH-major] Angioplasty, Balloon, Coronary / adverse effects. Coronary Artery Bypass / adverse effects. Coronary Stenosis / surgery. Drug-Eluting Stents / adverse effects

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608116.001).
  • [ISSN] 0785-3890
  • [Journal-full-title] Annals of medicine
  • [ISO-abbreviation] Ann. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


48. Chen SL, Ye F, Zhang JJ, Liu ZZ, Lin S, Zhu ZS, Sun XW, Li F, Zhang AP, Chen JG, Ji QJ, Qian J, Chen F, Kwan TW: Distal left main coronary bifurcation lesions predict worse outcome in patients undergoing percutaneous implantation of drug-eluting stents: results from the Drug-Eluting Stent for the Treatment of Left Main Disease (DISTAL) Study. Cardiology; 2009;113(4):264-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal left main coronary bifurcation lesions predict worse outcome in patients undergoing percutaneous implantation of drug-eluting stents: results from the Drug-Eluting Stent for the Treatment of Left Main Disease (DISTAL) Study.
  • OBJECTIVES: We investigated the clinical outcome of stenting of unprotected left main coronary artery (LMCA).
  • METHODS: We studied 164 patients with nonbifurcated LMCA lesions (group A) and 96 patients with distal bifurcated lesions (group B).
  • There were significant differences in major adverse cardiac events at 1 (p = 0.014) and 2 years (p = 0.002) between group B (19.8%, 25.0%) and group A (9.1%, 10.4%), mainly due to increased target-vessel revascularization (16.7, 21.9% in group B vs. 6.1, 7.3% in group A, p = 0.006 and 0.001, respectively).
  • The double-stent technique was associated with worse outcomes at 1 year in group B compared to group A.
  • Bifurcation lesions (HR 3.42, 95% CI 1.34-5.61, p = 0.001), diabetes (HR 2.68, 95% CI 2.01-12.11, p = 0.015), three-vessel disease (HR 0.83, 95% CI 0.27-0.96, p = 0.001), incomplete revascularization (HR 0.15, 95% CI 0.11-0.35, p = 0.001) and stent diameter (HR 5.05, 95% CI 2.71-10.01, p = 0.03) were the independent factors of major adverse cardiac events in the whole patient cohort.
  • CONCLUSION: Stenting unprotected distal bifurcated LMCA was associated with unfavorable results when compared to stenting other LMCA lesions.
  • [MeSH-major] Angioplasty, Balloon, Coronary / adverse effects. Coronary Angiography. Coronary Artery Disease / radiography. Coronary Artery Disease / therapy. Drug-Eluting Stents / adverse effects
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prevalence. Proportional Hazards Models. Registries. Risk Factors. Stroke Volume. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Cardiology. 2009;113(4):260-3 [19246904.001]
  • (PMID = 19246905.001).
  • [ISSN] 1421-9751
  • [Journal-full-title] Cardiology
  • [ISO-abbreviation] Cardiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


49. Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Kim JJ, Choo SJ, Chung CH, Lee JW, Park SW, Park SJ: Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol; 2010 Oct 19;56(17):1366-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry.
  • OBJECTIVES: This study sought to evaluate the long-term safety and effectiveness of percutaneous coronary intervention (PCI), as compared with coronary artery bypass grafting (CABG), for unprotected left main coronary artery (LMCA) disease.
  • BACKGROUND: Data on the long-term (beyond 5-year) comparative results of treatment of unprotected LMCA disease with stent implantation or CABG are limited.
  • METHODS: We performed a 10-year clinical follow-up of 350 patients with unprotected LMCA disease who underwent PCI with bare-metal stents (BMS) (n = 100) or CABG (n = 250) from January 1995 to April 1999, and 5-year clinical follow-up of 395 patients with unprotected LMCA disease who underwent PCI with drug-eluting stents (DES) (n = 176) or CABG (n = 219) from January 2003 to May 2004.
  • CONCLUSIONS: For the treatment of unprotected LMCA disease, PCI with stent implantation showed similar long-term mortality and rates of death, Q-wave MI, or stroke.
  • [MeSH-major] Coronary Artery Bypass. Coronary Artery Disease / therapy. Stents
  • [MeSH-minor] Coronary Disease / therapy. Drug-Eluting Stents / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myocardial Infarction / mortality. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20946993.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Dubois C, Dens J, Sinnaeve P, Belmans A, Van Cleemput J, Mendez M, Piessens J, Desmet W: Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting. Am J Cardiol; 2008 Jan 1;101(1):75-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting.
  • Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) is controversial.
  • In 143 patients who underwent PCI of the unprotected LMCA, 30-day mortality was compared with predicted cumulative risk-adjusted perioperative surgical mortality based on logistic European System for Cardiac Operative Risk Evaluation.
  • The overall major adverse cardiac event rate at 1 year was 34.3%, reflecting the high-risk profile of the patient population.
  • Angiographic follow-up in 90 of the 118 patients alive at 6 months showed binary restenosis of 6% in patients treated with drug-eluting stents versus 29% in patients receiving bare-metal stents (p < or =0.01).
  • In conclusion, PCI for unprotected LMCA disease was associated with acceptable short- and medium-term outcomes in patients at low to intermediate risk of bypass surgery.
  • However, in selected indications, PCI of the LMCA can offer an alternative to surgery, especially when using drug-eluting stents.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Artery Disease / mortality. Coronary Artery Disease / therapy

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157969.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biolimus A9; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


51. Park SJ, Kim YH: Percutaneous coronary intervention for unprotected left main coronary artery stenosis. Cardiol Clin; 2010 Feb;28(1):81-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous coronary intervention for unprotected left main coronary artery stenosis.
  • Because of the long-term benefit of coronary artery bypass graft (CABG) surgery in medical therapy, CABG has been the standard treatment of unprotected left main coronary artery (LMCA) stenosis.
  • However, with the advancement of techniques and equipment, the percutaneous interventional approach for implantation of coronary stents has been shown to be feasible for patients with unprotected LMCA stenosis.
  • The recent introduction of drug-eluting stents (DESs), together with advances in periprocedural and postprocedural adjunctive pharmacotherapies, has improved outcomes of percutaneous coronary interventions (PCIs) for these complex coronary lesions.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Coronary Stenosis / therapy
  • [MeSH-minor] Drug-Eluting Stents. Humans. Patient Selection. Prognosis

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19962051.001).
  • [ISSN] 1558-2264
  • [Journal-full-title] Cardiology clinics
  • [ISO-abbreviation] Cardiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 69
  •  go-up   go-down


52. Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Gwon HC, Jeong MH, Jang YS, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ: Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol; 2010 Jul 6;56(2):117-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry.
  • OBJECTIVES: We performed the long-term follow-up of a large cohort of patients in a multicenter study receiving left main coronary artery (LMCA) revascularization.
  • BACKGROUND: Limited information is available on long-term outcomes for patients with unprotected LMCA disease who underwent coronary stent procedure or coronary artery bypass grafting (CABG).
  • METHODS: We evaluated 2,240 patients with unprotected LMCA disease who received coronary stents (n = 1,102; 318 with bare-metal stents and 784 with drug-eluting stents) or underwent CABG (n = 1,138) between 2000 and 2006 and for whom complete follow-up data were available for at least 3 to 9 years (median 5.2 years).
  • Similar results were obtained in comparisons of bare-metal stent with concurrent CABG and of drug-eluting stent with concurrent CABG.
  • CONCLUSIONS: During 5-year follow-up, stenting showed similar rates of mortality and of the composite of death, Q-wave MI, or stroke but higher rates of TVR as compared with CABG for patients with unprotected LMCA disease.
  • [MeSH-major] Coronary Disease / therapy. Stents
  • [MeSH-minor] Coronary Artery Bypass. Drug-Eluting Stents. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20451344.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


53. Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kimura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, Lansky AJ, Collins M, Stone GW, Leon MB, Moses JW, Mehran R: Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis. Am J Cardiol; 2008 Mar 15;101(6):801-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis.
  • This study was aimed to evaluate outcomes of patients with unprotected left main coronary artery (LMCA) stenosis who were treated with drug-eluting stents.
  • Sixty-three consecutive patients with unprotected LMCA stenosis were treated with sirolimus-eluting stents in 52 (83%) patients and paclitaxel-eluting stents in 11 (17%) patients, in whom percutaneous intervention was considered the sole alternative because of high surgical risk and/or patient preference.
  • Involvement of the distal LMCA was observed in 46 (73%) patients.
  • In conclusion, drug-eluting stent placement for unprotected LMCA stenosis may be a feasible therapeutic alternative in patients at high surgical risk.
  • [MeSH-minor] Aged. Aged, 80 and over. Coronary Angiography. Electrocardiography. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / pharmacology. Male. Prospective Studies. Treatment Outcome. Tubulin Modulators / pharmacology. Ultrasonography, Interventional

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328844.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible; 0 / Immunosuppressive Agents; 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


54. Gotzmann M, Bojara W, Germing A, Mügge A, Laczkovics A, Thiessen C, Tannapfel A, Lindstaedt M: Differential diagnosis of non-atherosclerotic left main coronary artery stenosis. BMJ Case Rep; 2009;2009:bcr0820080776
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of non-atherosclerotic left main coronary artery stenosis.
  • A left main coronary artery (LMCA) stenosis without any atherosclerotic changes elsewhere in the coronary artery tree is a rare finding, and some uncommon reasons for luminal narrowing should be considered.
  • An unusual case of non-atherosclerotic LMCA stenosis is reported.A middle-aged patient presented with acute myocardial infarction.
  • An immediate coronary angiography was ordered and revealed a subtotal mid LMCA stenosis.
  • A drug-eluting stent was successfully implanted in the LMCA.Operative revascularisation was recommended.
  • Five years after the first admission to our hospital, the patient died as a result of ventricular fibrillation.The differential diagnosis of non-atherosclerotic LMCA stenoses is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Heart. 1997 Oct;78(4):419-20 [9404263.001]
  • [Cites] Int J Cardiol. 1997 Apr 18;59(2):209-11 [9158179.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):236-7 [12118767.001]
  • [Cites] Tex Heart Inst J. 2006;33(2):253-5 [16878640.001]
  • [Cites] Clin Cardiol. 1990 May;13(5):360-6 [2347127.001]
  • [Cites] J Rheumatol. 1990 May;17(5):708-11 [2359086.001]
  • [Cites] Circulation. 1983 May;67(5):1151-4 [6831677.001]
  • [Cites] Int J Cardiol. 1993 Sep;41(2):165-7 [8282441.001]
  • [Cites] Int J Cardiol. 1995 Sep;51(2):202-3 [8522418.001]
  • [Cites] Angiology. 1996 Mar;47(3):305-9 [8638877.001]
  • [Cites] Clin Cardiol. 1996 Jun;19(6):509-12 [8790958.001]
  • [Cites] Ann Thorac Surg. 1999 Jun;67(6):1789-91 [10391298.001]
  • [Cites] Ann Thorac Surg. 1999 Jun;67(6):1791-3 [10391299.001]
  • [Cites] Heart. 2000 Jan;83(1):91-3 [10618343.001]
  • [Cites] J Thorac Cardiovasc Surg. 1976 Jul;72(1):123-6 [1084447.001]
  • [Cites] Heart. 2000 Dec;84(6):E12 [11083756.001]
  • [Cites] J Invasive Cardiol. 2004 Feb;16(2):89-91 [14760201.001]
  • [Cites] Heart. 2004 Apr;90(4):e21 [15020539.001]
  • [Cites] Can J Cardiol. 2008 May;24(5):e30-2 [18464951.001]
  • (PMID = 21687045.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027375
  •  go-up   go-down


55. Ben-Dor I, Vaknin-Assa H, Lev E, Brosh D, Fuchs S, Assali A, Kornowski R: Clinical results of unprotected left main coronary stenting. Isr Med Assoc J; 2009 Mar;11(3):154-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical results of unprotected left main coronary stenting.
  • BACKGROUND: Although unprotected left main coronary artery disease is considered by contemporary guidelines to be an indication for surgery, percutaneous coronary intervention may be necessary in patients at high surgical risk.
  • OBJECTIVES: To assess the outcome of angioplasty in the treatment of unprotected LMCA disease.
  • METHODS: Angiographic and clinical data were collected prospectively for all patients who underwent emergent or nonemergent (planned) therapeutic PCI for unprotected LMCA disease at our center from 2003 to 2007.
  • Baseline values were compared with findings at 1, 6 and 12 months after the procedure.
  • Forty-nine percent of the procedures were performed with bare metal stents and 51% with drug-eluting stents.
  • The overall mortality rate was 11.3% at 1 month, 18.3% at 6 months and 19.7% at 12 months.
  • Elective PCI was associated with significantly lower mortality (2.3% vs. 25% at 1 month, 4.6% vs. 39% at 6 months and 6.9% vs. 39% at 12 months), and the use of drug-eluting stents was associated with lower rates of target vessel revascularization and major adverse cardiac events than use of bare metal stents (2.8% vs. 14% at 1 month, 8.3% vs. 43% at 6 and 12 months).
  • Variables that correlated with increased mortality or MACE at 6 and 12 months were cardiogenic shock, emergent PCI, ejection fraction < 35%, renal failure, distal left main stenosis location, and reference diameter < 3 mm.
  • CONCLUSIONS: PCI is a feasible and relatively safe therapeutic option for unprotected LMCA.
  • The use of drug-eluting stents may improve the intermediate-term restenosis rate.
  • [MeSH-minor] Aged. Coronary Angiography. Drug-Eluting Stents. Female. Humans. Male. Middle Aged. Stents. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544705.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


56. Valgimigli M, Chieffo A, Lefèvre T, Colombo A, Morice MC, Serruys PW: Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. EuroIntervention; 2007 Feb;2(4):435-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era.
  • BACKGROUND: Whether restenosis remains a major, and potentially fatal, complication after percutaneous intervention for left main coronary artery (LMCA) stenosis and whether routine surveillance angiography should be a necessary part of the follow-up of these patients in current drug eluting stent (DES) era is largely debatable.
  • METHODS AND RESULTS: Patients who underwent elective treatment of unprotected LMCA with DES in three referral centres in Europe were pooled as follows: i) 147 patients treated in Massy, between 12th August 2002 and 31st December 2004;.
  • At 1 year, the out-of-hospital cumulative incidence of cardiac death or MI was 2.4%.
  • CONCLUSIONS: Cardiac and sudden death and the incidence of stent thrombosis after LMCA intervention with DES were reasonably low and compared favourably with what reported in non-LMCA lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755282.001).
  • [ISSN] 1774-024X
  • [Journal-full-title] EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • [ISO-abbreviation] EuroIntervention
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


57. Nassar H, Gotsman I, Gerganski P, Moseri M, Lotan C, Gotsman M: Cutting balloon angioplasty and stent implantation for aorto-ostial lesions: clinical outcome and 1-year follow-up. Clin Cardiol; 2009 Apr;32(4):183-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Percutaneous interventions for aorto-ostial narrowing of native coronary arteries are challenging because of early elastic recoil after the procedure and the high restenosis rate.
  • HYPOTHESIS: The purpose of the study was to evaluate the clinical outcomes of cutting balloon angioplasty and stent implantation for aorto-ostial lesions with a 1-year clinical follow-up.
  • RESULTS: Forty-eight patients underwent balloon angioplasty; 36 of whom had lesions in the ostial right coronary artery, and 12 of whom had lesions in the left main coronary artery (LMCA).
  • This technique should be compared with implantation of drug-eluting stents (DESs) in a controlled study.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Stents

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19353700.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Kim WJ, Park DW, Yun SC, Lee JY, Lee SW, Kim YH, Lee CW, Park SW, Park SJ: Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study. JACC Cardiovasc Interv; 2009 Oct;2(10):956-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study.
  • OBJECTIVES: This study sought to investigate whether the outcome of drug-eluting stent (DES) treatment and that of coronary artery bypass grafting (CABG) differed in diabetic and nondiabetic patients with unprotected left main coronary artery (LMCA) disease.
  • BACKGROUND: Diabetes mellitus has been shown to be a risk factor for adverse events and a major determinant in selection of a revascularization strategy in patients with multivessel or LMCA disease.
  • METHODS: A total of 1,474 patients with unprotected LMCA stenosis who received DES (n = 784) or underwent CABG (n = 690) were examined.
  • We also did not observe a diabetes-associated excess risk of death (p(interaction) = 0.90 and 0.16), or a composite of death, Q-wave MI, or stroke (p(interaction) = 0.68 and 0.93), or TVR (p(interaction) = 0.23 and 0.92), between patients receiving either treatment.
  • CONCLUSIONS: The prognostic impact of diabetes on long-term treatment with DES or CABG for patients with unprotected LMCA disease was minimal.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Bypass. Coronary Stenosis / therapy. Diabetic Angiopathies / therapy
  • [MeSH-minor] Aged. Drug-Eluting Stents. Female. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. Myocardial Infarction / etiology. Proportional Hazards Models. Registries. Risk Assessment. Risk Factors. Severity of Illness Index. Stroke / etiology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JACC Cardiovasc Interv. 2009 Oct;2(10):964-6 [19850256.001]
  • (PMID = 19850255.001).
  • [ISSN] 1876-7605
  • [Journal-full-title] JACC. Cardiovascular interventions
  • [ISO-abbreviation] JACC Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Lichtman MA, Rowe JM: The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol; 2004 Apr;31(2):185-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of patient age to the pathobiology of the clonal myeloid diseases.
  • The incidence of the major clonal myeloid diseases, clonal cytopenias, acute, subacute (oligoblastic), and chronic myelogenous leukemia, polycythemia vera, thrombocythemia, and idiopathic myelofibrosis increases in a log-linear manner from young adulthood through advanced age.
  • This age effect is highlighted by the dramatically less favorable outcome in older than younger patients with acute myeloid leukemia with similar "favorable" cytogenetic changes.
  • In addition, in acute and subacute myeloid leukemia in older patients, the disease is intrinsically more resistant to therapy.
  • Overexpression of drug resistance genes and unfavorable genetic mutations are more prevalent in older patients and provide evidence that acute myeloid leukemia is often qualitatively different in these patients.
  • Although improved drug schedules have led to significant improvements in event-free survival in younger patients, these improvements have been far less evident in older patients.
  • New approaches, especially the development of drugs aimed at new targets, will be required to obtain a high frequency of long-term remissions in older patients.
  • Agents that reverse inherent cellular drug resistance, farnesyltransferase inhibitors, BCL-2 inhibitors, and FLT3 inhibitors are early examples of such approaches.
  • [MeSH-major] Leukemia, Myeloid

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15112149.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


60. Tefferi A: Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program; 2006;:240-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
  • JAK2V617F, a somatic gain-of-function mutation involving the JAK2 tyrosine kinase gene, occurs in nearly all patients with polycythemia vera (PV) but also in a variable proportion of patients with other myeloid disorders; mutational frequency is estimated at approximately 50% in both essential thrombocythemia (ET) and myelofibrosis (MF), up to 20% in certain subcategories of atypical myeloproliferative disorder (atypical MPD), less than 3% in de novo myelodysplastic syndrome (MDS) or acute myeloid leukemia, and 0% in chronic myeloid leukemia (CML).
  • Accordingly, there is now molecular justification for grouping PV, ET, and MF together in a distinct MPD category (i.e., classic, BCR-ABL(-) MPD) that is separate from chronic myeloid leukemia (CML), MDS, and atypical MPD.
  • Current information on disease-specific prognostic relevance of JAK2V617F is inconclusive and confounded by inter-study differences in the performance of mutation screening assays.
  • Regardless, the discovery of JAK2V617F has reinforced the pathogenetic contribution of JAK-STAT signaling in MPD and identifies JAK2 as a valid drug target.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124067.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 41
  •  go-up   go-down


61. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A, LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators: Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol; 2009 May 12;53(19):1760-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
  • OBJECTIVES: The aim of this trial was to compare the safety and efficacy of paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) for treatment of unprotected left main coronary artery (uLMCA) disease.
  • METHODS: In this randomized study, 607 patients with symptomatic coronary artery disease undergoing percutaneous coronary intervention for uLMCA were enrolled: 302 were assigned to receive a PES (Taxus, Boston Scientific, Natick, Massachusetts) and 305 assigned to receive a SES (Cypher, Cordis, Johnson & Johnson, New Brunswick, New Jersey).
  • The primary end point was the combined incidence of death, myocardial infarction, and target lesion revascularization (TLR) at 1 year.
  • The secondary end point was angiographic restenosis on the basis of the LMCA area analysis at follow-up angiography.
  • RESULTS: At 1 year the cumulative incidence of death, myocardial infarction, or TLR was 13.6% in the PES and 15.8% in the SES group (relative risk [RR]: 0.85, 95% confidence interval [CI]: 0.56 to 1.29, p = 0.44).
  • CONCLUSIONS: Implantation of either PES or SES in uLMCA lesions is safe and effective; both of these drug-eluting stents provide comparable clinical and angiographic outcomes. (Drug-Eluting-Stents for Unprotected Left Main Stem Disease [ISAR-LEFT-MAIN]; NCT00133237).
  • [MeSH-major] Coronary Artery Disease / drug therapy. Coronary Restenosis / drug therapy. Drug-Eluting Stents. Immunosuppressive Agents / therapeutic use. Paclitaxel / therapeutic use. Sirolimus / therapeutic use. Tubulin Modulators / therapeutic use
  • [MeSH-minor] Aged. Angioplasty, Balloon, Coronary. Confidence Intervals. Coronary Angiography. Female. Humans. Incidence. Male. Myocardial Infarction / drug therapy. Myocardial Infarction / therapy. Platelet Aggregation Inhibitors / therapeutic use. Risk. Ticlopidine / analogs & derivatives. Ticlopidine / therapeutic use

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Cardiol. 2009 May 12;53(19):1769-72 [19422983.001]
  • (PMID = 19422982.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00133237
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Platelet Aggregation Inhibitors; 0 / Tubulin Modulators; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


62. Lee JY, Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Park SW, Park SJ: Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry. J Am Coll Cardiol; 2009 Aug 25;54(9):853-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
  • OBJECTIVES: The aim of this study was to evaluate long-term clinical outcomes after implantation of sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) among patients with unprotected left main coronary artery (LMCA) disease.
  • BACKGROUND: There have been few comparisons of long-term outcomes among currently available drug-eluting stents (DES) for the treatment of LMCA disease.
  • METHODS: A total of 858 consecutive patients with unprotected LMCA stenosis were treated with SES (n = 669) or PES (n = 189) between May 2003 and June 2006.
  • CONCLUSIONS: In consecutive patients with unprotected LMCA disease undergoing DES implantation, SES and PES showed similar long-term clinical outcomes in terms of death, MI, repeat revascularization, and stent thrombosis.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Coronary Stenosis / therapy. Paclitaxel / administration & dosage. Sirolimus / administration & dosage
  • [MeSH-minor] Aged. Drug-Eluting Stents. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Treatment Outcome. Tubulin Modulators / therapeutic use

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 by the American College of Cardiology Foundation
  • (PMID = 19695467.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


63. Park SJ, Park DW: Left main stenting: is it a different animal? EuroIntervention; 2010 Dec;6 Suppl J:J112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left main stenting: is it a different animal?
  • For several decades, coronary-artery bypass grafting (CABG) has been regarded as the treatment of choice for patients with unprotected left main coronary artery (LMCA) disease.
  • However, because of marked advancements in techniques of percutaneous coronary intervention (PCI) with stenting and CABG, as well as adjunctive pharmacologic therapy, a new evaluation and review of current indications for optimal revascularisation therapy for LMCA disease may be required to determine the standard of care for these patients.
  • The available current evidence suggests that the composite outcome of death, myocardial infarction and stroke is similar in patients with LMCA disease who are treated with PCI with stenting or CABG, the only difference was the rate of repeat revascularisation.
  • Although PCI can be performed successfully in most LMCA lesions, "high-risk" anatomic subsets, especially involving distal LMCA bifurcation lesions, continue to present unique technical challenges to interventional cardiologists, and, therefore, an integrated approach combing advanced devices, tailored techniques, adjunctive support of physiologic and morphologic evaluation, and adjunctive pharmacologic agents should be reinforced to improve clinical outcomes.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Artery Disease / therapy. Stents
  • [MeSH-minor] Drug-Eluting Stents. Humans. Metals. Patient Selection. Prosthesis Design. Risk Assessment. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21930474.001).
  • [ISSN] 1969-6213
  • [Journal-full-title] EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • [ISO-abbreviation] EuroIntervention
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


64. Parodi G, Maehara A, Giuliani G, Kubo T, Mintz GS, Migliorini A, Valenti R, Carrabba N, Antoniucci D: Optical coherence tomography in unprotected left main coronary artery stenting. EuroIntervention; 2010 May;6(1):94-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical coherence tomography in unprotected left main coronary artery stenting.
  • AIMS: Delayed or incomplete stent endothelisation and stent malapposition may predispose to DES thrombosis that can be a catastrophic event in the left main coronary artery (LMCA).
  • OCT can accurately identify stent struts and arterial tissue, but is limited by the need of vessel blood clearance and penetration; also no data exist on its use in LMCA.
  • We sought to verify whether optical coherence tomography (OCT) can accurately assess arterial wall response after drug eluting stent (DES) implantation in the LMCA.
  • METHODS AND RESULTS: OCT images were obtained in 15 patients (mean age 70.7 + or - 8.0 years) six months after LMCA DES implantation.
  • Acquisitions were performed without proximal balloon occlusion during isoosmolar contrast injection through a 6 Fr guiding catheter without side holes at a speed of 2-3 mL/sec.
  • In five patients OCT detected abnormal intraluminal tissue, and in two cases this finding was related to uncovered struts.
  • CONCLUSIONS: OCT assessment of vascular response after LMCA DES implantation is safe and feasible.
  • Further development of OCT imaging technology will be necessary for complete evaluation of LMCA stents.
  • [MeSH-major] Angioplasty, Balloon, Coronary / instrumentation. Coronary Artery Disease / therapy. Coronary Vessels / pathology. Drug-Eluting Stents. Tomography, Optical Coherence

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20542803.001).
  • [ISSN] 1969-6213
  • [Journal-full-title] EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • [ISO-abbreviation] EuroIntervention
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


65. Vecchio S, Chechi T, Vittori G, Biondi Zoccai GG, Lilli A, Spaziani G, Giuliani G, Falchetti E, Margheri M: Outlook of drug-eluting stent implantation for unprotected left main disease: insights on long-term clinical predictors. J Invasive Cardiol; 2007 Sep;19(9):381-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outlook of drug-eluting stent implantation for unprotected left main disease: insights on long-term clinical predictors.
  • BACKGROUND: Percutaneous coronary intervention (PCI) has been increasingly employed to treat unprotected left main coronary artery (LMCA) stenosis, with variable success.
  • This strategy has been applied to patients undergoing drug-eluting stent (DES) implantation for unprotected LMCA stenosis.
  • METHODS: From April 2003 to June 2006, 114 consecutive patients with de novo unprotected LMCA stenosis underwent PCI with DES, and were followed over a mean period of 17.1 +/- 9.1 months.
  • RESULTS: LMCA stenting was successfully performed in all patients.
  • In-hospital mortality was 3.5%, with no in-hospital non-fatal MI or emergency coronary artery bypass grafts.
  • Acute coronary syndromes, as clinical presentation, and non-ostial LMCA disease were also significantly more common within non-surviving patients (100% vs. 67%; p < 0.05, and 92.3% vs. 66.3%; p = 0.05, respectively).
  • CONCLUSIONS: Stenting of unprotected LMCA appears to be associated with a favorable mid-term outlook, especially in selected patients.
  • [MeSH-major] Angioplasty, Balloon, Coronary / mortality. Coronary Artery Disease / therapy. Coronary Restenosis / prevention & control. Immunosuppressive Agents / administration & dosage. Sirolimus / administration & dosage. Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Phytogenic / administration & dosage. Coronary Angiography. Drug Delivery Systems. Female. Follow-Up Studies. Humans. Male. Paclitaxel / administration & dosage. Predictive Value of Tests. Prognosis. Prospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invasive Cardiol. 2007 Sep;19(9):388-9 [17827508.001]
  • (PMID = 17827507.001).
  • [ISSN] 1557-2501
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


66. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, Garcia-Garcia HM, Polad J, Tsuchida K, Regar E, Van der Giessen WJ, de Jaegere P, De Feyter P, Serruys PW: Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol; 2006 Apr 18;47(8):1530-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries.
  • OBJECTIVES: This study sought to investigate whether the anatomical location of the disease carries prognostic implications in patients undergoing drug-eluting stent (DES) implantation for the left main coronary artery (LMCA) stenosis.
  • BACKGROUND: Liberal use of DES, compared with a bare metal stent (BMS), has resulted in an improved outcome in patients undergoing LMCA intervention.
  • METHODS: From April 2002 to June 2004, 130 patients received DES as part of the percutaneous intervention for LMCA stenoses in our institution.
  • Distal LMCA disease (DLMD) was present in 94 patients.
  • They were at higher surgical risk and presented with a greater coronary disease extent compared with patients without DLMD.
  • CONCLUSIONS: Distal LMCA disease carries independent prognostic implications, and it may help in selecting the most appropriate patient subset for LMCA intervention beyond the conventional surgical risk status in the DES era.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Coronary Angiography. Coronary Disease / radiography. Coronary Disease / therapy. Paclitaxel / administration & dosage. Sirolimus / administration & dosage. Stents

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630987.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


67. Tanaka N, Terashima M, Kinoshita Y, Kimura M, Nasu K, Ehara M, Tsuchikane E, Matsubara T, Asakura Y, Katoh O, Suzuki T: Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation. J Invasive Cardiol; 2008 Oct;20(10):505-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
  • BACKGROUND: The impact of plaque debulking with directional coronary atherectomy (DCA) prior to single sirolimus-eluting stent (SES) implantation in an unprotected left main coronary artery (LMCA) involving bifurcation stenosis has not been fully evaluated.
  • METHODS: One hundred and one patients with unprotected LMCA bifurcation lesions treated with single SES implantation (from the LMCA to the left descending coronary artery [LAD] across the left circumflex artery [LCx] ostium) were divided into 2 groups: DCA group (n = 41, plaque debulking with DCA prior to SES implantation) and non-DCA group (n = 60, single SES implantation alone).
  • RESULTS: At 1-year follow up, freedom from major adverse cardiac events was 97.4 +/- 2.6% in the DCA group, and 88.6 +/- 4.4% in the non-DCA group (p = 0.129).
  • [MeSH-major] Angioplasty, Balloon, Coronary / methods. Coronary Artery Disease / surgery. Coronary Vessels / surgery. Drug-Eluting Stents / adverse effects. Sirolimus / therapeutic use

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829993.001).
  • [ISSN] 1557-2501
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; R16CO5Y76E / Aspirin; W36ZG6FT64 / Sirolimus
  •  go-up   go-down






Advertisement